

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A Saudi Joint Stock Company)

**CONSOLIDATED FINANCIAL STATEMENTS**  
For the year ended 31 December 2024  
together with the Independent Auditor's Report

**MOUWASAT MEDICAL SERVICES COMPANY  
(A SAUDI JOINT STOCK COMPANY)**

**CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

---

<b>INDEX</b>	<b>Page</b>
Independent auditor's report	-
Consolidated statement of financial position	1
Consolidated statement of profit or loss and other comprehensive income	2
Consolidated statement of changes in equity	3
Consolidated statement of cash flows	4 - 5
Notes to the consolidated financial statements	6 - 52



## KPMG Professional Services Company

16<sup>th</sup> Floor, Al Barghash Tower  
6189 Prince Turki Road, Al Corniche  
P. O. Box 4803  
Al Khobar, 34412 - 3146  
Kingdom of Saudi Arabia  
Commercial Registration No 2051062328

Headquarters in Riyadh

## شركة كي بي إي للاستشارات المهنية مساهمة مهنية

الطابق ١٦، برج البرغاش  
٦١٨٩ طريق الأمير تركي، الكورنيش  
ص.ب ٤٨٠٣  
الخبير ٣٤٤١٢ - ٣١٤٦  
المملكة العربية السعودية  
سجل تجاري رقم ٢٠٥١٠٦٢٣٢٨

المركز الرئيسي في الرياض

# Independent Auditor's Report

To the Shareholders of Mouwasat Medical Services Company (A Saudi Joint Stock Company)

## Opinion

We have audited the consolidated financial statements of **Mouwasat Medical Services Company ("the Company") and its subsidiaries ("the Group")**, which comprise the consolidated statement of financial position as at 31 December 2024, the consolidated statements of profit or loss and other comprehensive income, changes in equity and cash flows for the year then ended, and notes to the consolidated financial statements, comprising material accounting policies and other explanatory information.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as at 31 December 2024, and its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IFRS Accounting Standards) that are endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements issued by the Saudi Organization for Chartered and Professional Accountants (SOCPA).

## Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the consolidated Financial Statements section of our report. We are independent of the Group in accordance with the International Code of Ethics for Professional Accountants (including International Independence Standards), that is endorsed in the Kingdom of Saudi Arabia, that are relevant to our audit of the consolidated financial statements, and we have fulfilled our other ethical responsibilities in accordance with the Code's requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

KPMG Professional Services Company, a professional closed joint stock company registered in the Kingdom of Saudi Arabia with a paid-up capital of SAR100,000,000 and a non-partner member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. Commercial Registration of the headquarters in Riyadh is: 1010425494.

شركة كي بي إي للاستشارات المهنية مساهمة مهنية، شركة مساهمة مهنية عجلة مسجلة في المملكة العربية السعودية، رأس مالها (١٠٠٠٠٠٠٠٠٠٠) ريال سعودي مدفوع بالكامل، وهي عضو غير تريك في الشبكة العالمية لشركات كي بي إي المسجلة والتابعة لـ كي بي إي العالمية المحدودة، شركة الجبزية خاصة محدودة بالاعتماد، رقم السجل التجاري للمركز الرئيسي في الرياض هو: ١٠١٠٤٢٥٤٩٤.



# Independent Auditor's Report

To the Shareholders of Mouwasat Medical Services Company (A Saudi Joint Stock Company) (continued)

Key Audit Matters (continued)	
Revenue recognition	
Refer Note 3(e) and 4(a)(iii) for the accounting policy and estimate relating to revenue recognition and Note 28 for revenue disclosure.	
The key audit matter	How the matter was addressed in our audit
<p>During the year ended 31 December 2024, the Group recognized revenue of SR 2.879 billion (2023: SR 2.706 billion).</p> <p>The Group recognizes revenue upon satisfaction of performance obligation related to medical and related services at the consideration to which the Group expects to be entitled in exchange for those goods or services.</p> <p>Certain contracts with customers include variable consideration such as volume discounts, prompt payment discounts and adjustment of invoice amount. These adjustments constitute variable consideration and are considered in the recognition of revenue on an estimated basis in the period in which the related services are rendered.</p> <p>Revenue recognition is considered as a key audit matter because the estimation of the variable consideration involves significant judgement and estimates in determining the amount.</p>	<p>We performed the following among other procedures:</p> <ul style="list-style-type: none"> <li>- Assessed the appropriateness of the Group's revenue recognition accounting policies by considering the requirements of relevant accounting standards;</li> <li>- Assessed the design and implementation and tested (on a sample basis) the operating effectiveness of the Group's key internal control in relation to the estimates of variable consideration;</li> <li>- Assessed the appropriateness of significant accounting judgments, estimates and assumptions made by management to determine the variable consideration;</li> <li>- Performed a retrospective review (on a sample basis) of actual claims settled to the original gross claims;</li> <li>- Performed tests (on a sample basis) of settlements and claims with major customers of the Group; and</li> <li>- Assessed the adequacy of relevant disclosures and presentation in the consolidated financial statements.</li> </ul>



# Independent Auditor's Report

To the Shareholders of Mouwasat Medical Services Company (A Saudi Joint Stock Company) (continued)

Key Audit Matters (continued)	
Valuation of accounts receivables	
Refer Note 3(l)(i) and 4(a)(i) for the accounting policy and estimate related to impairment loss based on expected credit losses (ECLs) and Note 14 for accounts receivable disclosure.	
The key audit matter	How the matter was addressed in our audit
<p>During the year ended 31 December 2024, the gross carrying amount of accounts receivables amounted to SR 1.017 billion (2023: SR 1.316 billion). The impairment loss based on ECLs on these receivables amount to SR 92.4 million (2023: SR 163.5 million).</p> <p>The Group's management has applied a simplified expected credit loss ("ECL") model to determine the impairment loss of accounts receivables. The provision rates are based on days past due for groupings of various customer segments that have similar loss patterns (i.e. payor groups). The provision matrix is initially based on the Group's historical observed default rates. The Group calibrate the matrix to adjust the historical credit loss experience with forward-looking information.</p> <p>We considered this a key audit matter due to the judgements and estimation involved in assessing the recoverability of outstanding trade receivable and determining the impairment thereon as per the requirement of IFRS 9 Financial Instruments.</p>	<p>We performed the following among other procedures:</p> <ul style="list-style-type: none"> <li>- Obtained an understanding of management's processes, systems and controls over trade receivables;</li> <li>- Evaluated the appropriateness of the accounting policies of the Group and evaluating these against the requirements of FRS 9 Financial Instruments;</li> <li>- Evaluated the reasonableness of management's key judgements and estimates made, including selection and application of methods, models, significant assumptions, data sources and selection of the point estimate and retrospective testing;</li> <li>- Evaluated the competence of management expert and checked the completeness, accuracy and relevance of data shared with management expert.</li> <li>- Involved our own specialist to assess the working and evaluate the assumptions made by the management expert in the model and working used.</li> <li>- Tested the basis of specific provisions based on historic data, ageing and collection trends; and</li> <li>- Assessed the reasonableness and adequacy of disclosures and presentation in the consolidated financial statements.</li> </ul>



# Independent Auditor's Report

To the Shareholders of Mouwasat Medical Services Company (A Saudi Joint Stock Company) (continued)

## Other Information

Management is responsible for the other information. The other information comprises the information included in the annual report but does not include the consolidated financial statements and our auditor's report thereon. The annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the consolidated financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we read the annual report, when made available to us, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.

## Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with IFRS Accounting Standards that are endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements issued by SOCPA, the applicable requirements of the Regulations for Companies and Company's By-laws and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, the Audit Committee are responsible for overseeing the Group's financial reporting process.

## Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. 'Reasonable assurance' is a high level of assurance, but is not a guarantee that an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.



## Independent Auditor's Report

To the Shareholders of Mouwasat Medical Services Company (A Saudi Joint Stock Company) (continued)

### Auditor's Responsibilities for the Audit of the Consolidated Financial Statements (continued)

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, then we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Plan and perform the group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the group as a basis for forming an opinion on the group financial statements. We are responsible for the direction, supervision and review of the audit work performed for purposes of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit of **Mouwasat Medical Services Company ("the Company") and its subsidiaries ("the Group")**.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

### KPMG Professional Services Company

**Mohammed Najeeb Alkhelaiwi**  
License no. 481



Al Khobar, 10 Ramadan 1446H  
Corresponding to: 10 March 2025G





**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)


**CONSOLIDATED STATEMENT OF FINANCIAL POSITION**  
**AS AT 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

	Note	2024	2023
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property and equipment	7	3,509,651,696	3,046,129,447
Goodwill	8	16,371,000	16,371,000
Intangible assets	9	20,184,315	20,186,569
Right-of-use asset	10	20,090,410	19,683,031
Investment in an associate	11	-	-
Advances to contractors and suppliers	12	80,074,990	244,460,781
<b>Total non-current assets</b>		<b>3,646,372,411</b>	<b>3,346,830,828</b>
<b>Current assets</b>			
Inventories	13	232,064,997	197,164,786
Accounts receivables	14	925,047,643	1,152,656,746
Due from a related party	35	-	916,431
Advances, prepayments and other current assets	15	87,739,936	98,957,277
Term deposits	16	85,000,000	100,000,000
Cash and cash equivalents	17	426,574,756	49,049,506
Investment in associate - held for sale	11	-	18,971,023
<b>Total current assets</b>		<b>1,756,427,332</b>	<b>1,617,715,769</b>
<b>Total assets</b>		<b>5,402,799,743</b>	<b>4,964,546,597</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Share capital	18	2,000,000,000	2,000,000,000
Statutory reserve	20	430,344,695	365,768,791
Retained earnings		1,137,993,239	911,287,213
<b>Equity attributable to shareholders of the Company</b>		<b>3,568,337,934</b>	<b>3,277,056,004</b>
Non-controlling interest	21	145,232,079	149,790,712
<b>Total equity</b>		<b>3,713,570,013</b>	<b>3,426,846,716</b>
<b>Liabilities</b>			
<b>Non-current liabilities</b>			
Long-term borrowings	22	564,793,854	500,049,694
Employees' benefits	23	173,427,385	153,800,438
Lease liabilities	24	19,453,753	18,783,185
Retention payable	25.1	50,476,948	34,434,661
<b>Total non-current liabilities</b>		<b>808,151,940</b>	<b>707,067,978</b>
<b>Current liabilities</b>			
Accounts payable	25	276,850,508	231,706,734
Due to related parties	35	8,228,796	5,136,187
Accruals and other current liabilities	26	228,455,456	184,304,042
Refund liability	28.2	155,993,839	106,084,803
Current maturity of lease liabilities	24	3,842,154	3,612,000
Current portion of long-term borrowings	22	173,589,172	266,034,059
Provision for zakat	27	34,117,865	33,754,078
<b>Total current liabilities</b>		<b>881,077,790</b>	<b>830,631,903</b>
<b>Total liabilities</b>		<b>1,689,229,730</b>	<b>1,537,699,881</b>
<b>Total equity and liabilities</b>		<b>5,402,799,743</b>	<b>4,964,546,597</b>

  
Nassir Aljubaei  
(Chief Executive Officer)

  
Khalid Al-Saleem  
(Authorized Board Representative)

  
Yusuf Sulaiman  
(Chief Financial Officer)

The accompanying notes 1 through 40 on pages 6 to 52 form an integral part of these consolidated financial statements.



**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

	Notes	2024	2023
<b>Revenue</b>			
Medical services revenue	28	2,428,198,536	2,312,553,391
Pharmaceutical sales	28	451,173,805	392,954,730
		<u>2,879,372,341</u>	<u>2,705,508,121</u>
<b>Cost of revenue</b>			
Cost of operations	29	(1,281,055,232)	(1,109,986,629)
Cost of sales		(309,352,574)	(282,442,254)
		<u>(1,590,407,806)</u>	<u>(1,392,428,883)</u>
<b>Gross profit</b>		<b>1,288,964,535</b>	<b>1,313,079,238</b>
Selling and marketing expenses	30	(118,108,560)	(110,215,067)
General and administrative expenses	31	(376,392,004)	(337,427,376)
Impairment loss on accounts receivables	14.1	(78,406,331)	(117,256,160)
Other income	32	18,900,210	8,675,713
Other expenses	11	(10,686,634)	-
<b>Operating profit</b>		<b>724,271,216</b>	<b>756,856,348</b>
Finance income		11,979,959	6,482,135
Finance cost	33	(30,455,304)	(46,456,505)
Share of result of an associate	11	-	10,205,829
<b>Profit before zakat</b>		<b>705,795,871</b>	<b>727,087,807</b>
Zakat expense	27	(36,185,714)	(38,699,067)
<b>Profit for the year</b>		<b>669,610,157</b>	<b>688,388,740</b>
<b>Other comprehensive income</b>			
<i>Items that will not be reclassified to profit or loss:</i>			
Re-measurement loss on employees' end-of-service benefits obligations	23	(3,976,860)	(3,404,169)
Re-measurement loss on employee's retirement benefit obligations of the associate	11	-	(171,060)
<b>Other comprehensive loss for the year</b>		<b>(3,976,860)</b>	<b>(3,575,229)</b>
<b>Total comprehensive income for the year</b>		<b>665,633,297</b>	<b>684,813,511</b>
<b>Profit for the year attributable to:</b>			
Shareholders of the Company		645,759,043	657,687,906
Non-controlling interest	21	23,851,114	30,700,834
<b>Profit for the year</b>		<b>669,610,157</b>	<b>688,388,740</b>
<b>Total comprehensive income for the year attributable to:</b>			
Shareholders of the Company		641,281,930	654,209,580
Non-controlling interest	21	24,351,367	30,603,931
<b>Total comprehensive income for the year</b>		<b>665,633,297</b>	<b>684,813,511</b>
<b>Earnings per share:</b>			
Basic and diluted earnings per share for profit attributable to the shareholders of the Company	34	3.23	3.29

Nasser Alsubaei  
(Chief Executive Officer)

Khalid Al-Saleem  
(Authorized Board Representative)

Yusuf Sulaiman  
(Chief Financial Officer)


The accompanying notes 1 through 40 on pages 6 to 52 form an integral part of these consolidated financial statements.


**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)


**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

Notes	Attributable to the shareholders of the Company				Non-controlling interest	Total equity	
	Share capital	Statutory reserve	Retained earnings	Total shareholders' equity			
Balance at 1 January 2023	1,000,000,000	300,000,000	1,622,846,424	2,922,846,424	153,486,781	3,076,333,205	
<i>Total comprehensive income for the year</i>							
Profit for the year	-	-	657,687,906	657,687,906	30,700,834	688,388,740	
Other comprehensive loss for the year	-	-	(3,478,326)	(3,478,326)	(96,903)	(3,575,229)	
Total comprehensive income for the year	-	-	654,209,580	654,209,580	30,603,931	684,813,511	
Transfer to statutory reserve	20	- 65,768,791	(65,768,791)	-	-	-	
<i>Transactions with owners in their capacity as owners</i>							
Dividend	19	-	(300,000,000)	(300,000,000)	-	(300,000,000)	
Dividend to non-controlling interest	21	-	-	-	(34,300,000)	(34,300,000)	
Increase in share capital	18	1,000,000,000	(1,000,000,000)	-	-	-	
Balance at 31 December 2023		2,000,000,000	365,768,791	911,287,213	3,277,056,004	149,790,712	3,426,846,716
<b>Balance at 1 January 2024</b>		<b>2,000,000,000</b>	<b>365,768,791</b>	<b>911,287,213</b>	<b>3,277,056,004</b>	<b>149,790,712</b>	<b>3,426,846,716</b>
Acquisition of subsidiary	1	-	-	-	490,000	490,000	
<i>Total comprehensive income for the year</i>							
Profit for the year		-	-	645,759,043	645,759,043	23,851,114	669,610,157
Other comprehensive (loss) / gain for the year		-	-	(4,477,113)	(4,477,113)	500,253	(3,976,860)
<b>Total comprehensive income for the year</b>		-	-	<b>641,281,930</b>	<b>641,281,930</b>	<b>24,351,367</b>	<b>665,633,297</b>
Transfer to statutory reserve	20	-	64,575,904	(64,575,904)	-	-	
<i>Transactions with owners in their capacity as owners</i>							
Dividend	19	-	-	(350,000,000)	(350,000,000)	-	(350,000,000)
Dividend to non-controlling interests	21	-	-	-	(29,400,000)	(29,400,000)	
<b>Balance at 31 December 2024</b>		<b>2,000,000,000</b>	<b>430,344,695</b>	<b>1,137,993,239</b>	<b>3,568,337,934</b>	<b>145,232,079</b>	<b>3,713,570,013</b>

  
Nassir Alsubaei  
(Chief Executive Officer)

  
Khalid Al-Saleem  
(Authorized Board Representative)

  
Yusuf Sulaiman  
(Chief Financial Officer)

The accompanying notes 1 through 40 on pages 6 to 52 form an integral part of these consolidated financial statements.





**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)


**CONSOLIDATED STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

	Notes	2024	2023
<b>Cash flows from operating activities</b>			
Profit for the year		669,610,157	688,388,740
<i>Adjustments for:</i>			
Depreciation on property and equipment	7	228,445,620	214,957,726
Depreciation on right-of-use asset	10	3,005,346	2,811,862
Amortization of intangible assets	9	6,542,922	5,703,196
Impairment loss on accounts receivables	14	78,406,331	117,256,160
Share of results of an associate	11	-	(10,205,829)
Loss on sale of investment held for sale	11	480,805	-
Finance cost	33	30,455,304	46,456,505
Interest income on term deposits		(11,979,959)	(6,482,135)
Property and equipment written off		100	65,642
Gain on modification of leases	24.2	-	(393,525)
Dividend income from investment held for sale	11	(10,205,829)	-
Impairment loss on remeasurement of investment held for sale	11	10,205,829	-
Provision for employees' benefits	23	33,584,083	31,414,774
Gain on disposal of property and equipment	32	(1,183,251)	(292,893)
Zakat expense	27	36,185,714	38,699,067
		<u>1,073,553,172</u>	<u>1,128,379,290</u>
<i>Changes in:</i>			
Inventories		(34,900,211)	6,222,441
Accounts receivables		149,202,772	(233,483,979)
Due from a related party		916,431	1,406,777
Advances, prepayments and other current assets		12,104,313	(21,781,817)
Retention payable		16,042,287	6,371,035
Accounts payable		45,143,774	16,399,823
Due to related parties		3,092,609	(1,536,475)
Accruals and other current liabilities		44,032,917	10,744,766
Refund liabilities		49,909,036	976,028
<b>Cash generated from operating activities</b>		<u>1,359,097,100</u>	<u>913,697,889</u>
Employees' benefits paid	23	(17,933,996)	(18,098,353)
Finance cost paid	37.1	(48,912,598)	(50,894,189)
Zakat paid	27	(35,821,927)	(30,922,279)
<b>Net cash from operating activities</b>		<u>1,256,428,579</u>	<u>813,783,068</u>
<b>Cash flows from investing activities</b>			
Purchase of property and equipment		(429,017,800)	(277,038,015)
Purchase of intangible assets	9	(6,540,668)	(9,500,465)
Proceeds from disposal of property and equipment		1,842,756	791,300
Dividend received from an investment held for sale	11	10,205,829	9,852,121
Advances to contractors		(78,857,632)	(215,617,973)
Term deposits		15,000,000	11,000,000
Interest received on term deposits		11,092,987	5,810,643
Proceeds from sale of investment held for sale	11	8,284,389	-
Acquisition of subsidiary	1	490,000	-
<b>Net cash used in investing activities</b>		<u>(467,500,139)</u>	<u>(474,702,389)</u>

  
Nassir Al-Surraei  
(Chief Executive Officer)

  
Khalid Al-Saleem  
(Authorized Board Representative)


  
Yusuf Sulaiman  
(Chief Financial Officer)

The accompanying notes 1 through 40 on pages 6 to 52 form an integral part of these consolidated financial statements.

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**CONSOLIDATED STATEMENT OF CASH FLOWS (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

	Notes	2024	2023
<b>Cash flows from financing activities</b>			
Dividends paid	19	(350,000,000)	(300,000,000)
Proceeds from term loans	22	245,000,000	180,000,000
Repayment of term loans	22	(272,700,727)	(276,382,666)
Payment of lease liabilities including finance cost	24	(4,302,463)	(3,225,000)
Dividends paid to non-controlling interests in subsidiary	21	(29,400,000)	(34,300,000)
<b>Net cash outflow from financing activities</b>		<b>(411,403,190)</b>	<b>(433,907,666)</b>
Net increase / (decrease) in cash and cash equivalents		377,525,250	(94,826,987)
Cash and cash equivalents at beginning of the year		49,049,506	143,876,493
<b>Cash and cash equivalents at end of the year</b>	17	<b>426,574,756</b>	<b>49,049,506</b>
<b>Non-cash transactions:</b>			
Finance cost capitalized	7.4	20,366,251	4,539,066
Transfer from advances to contractors and suppliers to property and equipment	12	243,243,423	171,679,937
Addition of right of use asset	10	3,412,725	-
Addition of lease liability	24	3,412,725	-
Modification of right-of-use asset	10	-	(5,101,263)
Modification in lease liability	24	-	(5,494,788)

  
Nassir Alsubaei  
(Chief Executive Officer)

  
Khalid Al-Saeem  
(Authorized Board Representative)

  
Yusuf Sulaiman  
(Chief Financial Officer)

The accompanying notes 1 through 40 on pages 6 to 52 form an integral part of these consolidated financial statements.

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

**1. GENERAL**

Mouwasat Medical Services Company ("the Company") is registered in Saudi Arabia under Commercial Registration number 2050032029 dated Ramadan 12, 1417H (corresponding to January 21, 1997). The Company was converted into a Saudi Joint Stock Company in accordance with Ministerial Resolution No. 1880 dated Dhu-al-Hijja 4, 1426H (corresponding to 4 January 2006).

Details regarding the Company's subsidiary are as follows:

<b>Name</b>	<b>Country of incorporation</b>	<b>Activities</b>	<b>Percentage %</b>
Eastern Medical Services Company Limited	Saudi Arabia	Medical services	51%
Jeddah Doctor Company	Saudi Arabia	Medical services	51%
Modawaa and Rieaya Medical Company Limited	Saudi Arabia	Medical services	51%

Eastern Medical Services Company Limited is a limited liability company registered in the Kingdom of Saudi Arabia under commercial registration number 2051023824 dated Ramadan 10, 1420H (corresponding to 18 December 1999). This subsidiary is engaged in construction and operation of hospitals, dispensaries and special clinics.

Jeddah Doctors Company Limited ("JDC") (Saudi Closed Joint Stock Company) is registered in Kingdom of Saudi Arabia under commercial registration number 4030278617 dated Muharram 13, 1436H (corresponding to 6 November 2014). The subsidiary is engaged in general construction of non-residential buildings including (schools, hospitals, hotels etc.), demolition of buildings; purchase, sale and division of land and real estate, and off-plan sales activities; colleges and university institutes, hospitals, medical operation of hospitals.

Mouwasat Medical Services Company in partnership with Al Dawaa Medical Services Company, has established Modawaa and Rieaya Medical Company Limited ("Modawaa") a limited liability company within Kingdom of Saudi Arabia under commercial registration number 2051256627 dates Dhu'al Qadah 29, 1445H (corresponding to 6 June 2024) for the purpose of medical clinics activities. Modawaa's capital has been set at SR 1 million, with contributions divided as 51% for Mouwasat Medical Services Company and 49% for Al Dawaa Medical Services Company. The Company has control over Modawaa and classified it as a subsidiary. The operation of Modawaa has not yet commenced.

The Company through its multiple branches is engaged in the acquisition, management, operation and maintenance of hospitals, medical centers, drug stores, pharmacies and wholesale of medical equipment and drugs.

<b>Branch</b>	<b>Commercial Registration Number</b>	<b>Date</b>
Dammam	2050046891	18/09/1425H
Dammam	2050111494	20/04/1438H
Dammam	2050111780	25/05/1438H
Dammam	2050086573	27/11/1433H
Khobar	2051064380	12/09/1438H
Jubail	2055004626	09/03/1421H
Jubail	2055006727	19/09/1425H
Madinah	4650029967	06/05/1421H
Madinah	4650030759	11/11/1421H
Madinah	4650083001	18/01/1438H
Madinah	4650252425	19/05/1444H
Riyadh	1010295838	09/11/1431H
Yanbu	4700118283	04/06/1444H

The consolidated financial statements include the financial information of the branches mentioned above and its subsidiaries (together referred as 'Group').

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**2. BASIS OF PREPARATION**

**2.1. Statement of compliance**

These consolidated financial statements have been prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IFRS Accounting Standards) as endorsed in the Kingdom of Saudi Arabia (KSA) and other standards and pronouncements that are issued by Saudi Organization for Chartered and Professional Accountants (“SOCPA”) (here and after referring to as “IFRSs as endorsed in KSA”)

**2.2. Basis of measurement**

These consolidated financial statements have been prepared on a historical cost basis except for employees’ end-of-service benefits obligation which is measured at the present value of the obligations as explained in the relevant accounting policy, financial assets at fair value through profit or loss which are measure at fair value and financial assets at fair value through other comprehensive income which are measure at fair value.

**2.3. Functional and presentation currency**

These consolidated financial statements are presented in Saudi Riyals (SR) which is the Group’s functional currency. All financial information presented in these financial statements have been rounded off to the nearest Saudi Riyals, unless otherwise stated.

**3. MATERIAL ACCOUNTING POLICIES**

The accounting policies stated below have been consistently applied to all periods presented in these consolidated financial statements, unless otherwise stated.

**a) Basis of consolidation**

The consolidated financial statements comprise the consolidated financial statements of the Company (Parent Company) and its subsidiary as at 31 December 2024. Subsidiaries are all the entities over which the Group has control. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.

Specifically, the Group controls an investee if, and only if, the Group has:

- Power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee)
- Exposure, or rights, to variable returns from its involvement with the investee
- The ability to use its power over the investee to affect its returns

Generally, there is a presumption that a majority of voting rights results in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- The contractual arrangement(s) with the other vote holders of the investee
- Rights arising from other contractual arrangements
- The Group's voting rights and potential voting rights

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**a) Basis of consolidation (continued)**

The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income (OCI) are attributed to the equity holders of the Parent Company and non-controlling interest, even if this results in the non-controlling interest having a deficit balance.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies in line with the Group's accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions among members of the Group are eliminated in full on consolidation.

*Changes in ownership interests*

The Group treats transactions with non-controlling interests that do not result in a loss of control as transactions with equity owners of the Parent. A change in ownership interest results in an adjustment between the carrying amounts of the controlling and non-controlling interests to reflect their relative interests in the subsidiary. Any difference between the amount of the adjustment to non-controlling interests and any consideration paid or received is recognized within equity attributable to owners of the Parent Company.

*Loss of control*

When the Group loses control over a subsidiary, it derecognizes the assets and liabilities of the subsidiary, and any related NCI and other components of equity. Any resulting gain or loss is recognized in profit or loss. Any interest retained in the former subsidiary is measured at fair value when control is lost. This fair value becomes the initial carrying amount for the purposes of subsequently accounting for the retained interest as an associate or financial asset. In addition, any amounts previously recognized in other comprehensive income in respect of that entity are accounted for as if the Group had directly disposed of the related assets or liabilities.

*Non-Controlling Interests (NCI)*

Non-Controlling interests (NCI) are measured at their proportionate share of the acquiree's identifiable net assets at the date of acquisition. Changes in the Group's interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

*Interests in equity accounted investees*

The Group's interest in equity-accounted investees comprise interest in an associate.

Associates are those entities in which the Group has significant influence, but not control or joint control, over the financial and operating policies of these entities. Significant influence is presumed to exist when the Group holds between 20% and 50% of the voting rights. Investments in associates are accounted for using the equity method.

Under the equity method of accounting, the investments are initially recognized at cost and adjusted thereafter to recognize the group's share of the post-acquisition profits or losses of the investee in profit or loss, and the group's share of movements in other comprehensive income of the investee in other comprehensive income, until the date on which significant influence ceases. Goodwill relating to the associate is included in the carrying amount of the investment and is not tested for impairment separately. Dividends received or receivable from associates are recognized as a reduction in the carrying amount of the investment.

When the Group's share of losses in an equity accounted investment equals or exceeds its investment in the investee, the carrying amount of the investment, together with any long-term interests that form part thereof, is reduced to zero, and the recognition of further losses is discontinued except to the extent that the Group has incurred obligation or has made payments on behalf of the investee.



**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**a) Basis of consolidation (continued)**

Unrealised gains on transactions between the Group and its associates are eliminated to the extent of the Group's interest in these entities. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of equity-accounted investees have been changed where necessary to ensure consistency with the policies adopted by the Group.

The aggregate of the Group's share of profit or loss of an associate is shown on the face of the statement of profit or loss. The carrying amount of equity-accounted investments is tested for impairment in accordance with the policy described in the relevant accounting policy.

*Transactions eliminated on consolidation*

Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated. Unrealized gains arising from transactions with equity accounted investees are eliminated against the investment to the extent of the Group's interest in the investee. Unrealized losses are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment.

**b) Business combination**

The Group accounts for business combinations using the acquisition method when the acquired set of activities and assets meets the definition of a business and control is transferred to the Group. In determining whether a particular set of activities and assets is a business, the Group assesses whether the set of assets and activities acquired includes, at a minimum, an input and substantive process and whether the acquired set has the ability to produce outputs.

The Group has an option to apply a 'concentration test' that permits a simplified assessment of whether an acquired set of activities and assets is not a business. The optional concentration test is met if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.

The acquisition of an asset or a group of assets that does not constitute a business. In such cases the acquirer shall identify and recognise the individual identifiable assets acquired (including those assets that meet the definition of, and recognition criteria for, intangible assets in IAS 38 Intangible Assets) and liabilities assumed. The cost of the group shall be allocated to the individual identifiable assets and liabilities on the basis of their relative fair values at the date of purchase. Such a transaction or event does not give rise to goodwill.

Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, which is measured at acquisition date fair value, and the amount of any non-controlling interests in the acquiree. For each business combination, the Group elects whether to measure the non-controlling interests in the acquiree at fair value or at the proportionate share of the acquiree's identifiable net assets. Acquisition-related costs are expensed as incurred and included in administrative expenses.

Goodwill is initially measured at cost (being the excess of the aggregate of the consideration transferred and the amount recognised for non-controlling interests and any previous interest held over the net identifiable assets acquired and liabilities assumed). If the fair value of the net assets acquired is in excess of the aggregate consideration transferred, the Group re-assesses whether it has correctly identified all of the assets acquired and all of the liabilities assumed and reviews the procedures used to measure the amounts to be recognised at the acquisition date. If the reassessment still results in an excess of the fair value of net assets acquired over the aggregate consideration transferred, then the gain is recognised in profit or loss.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group's cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units.

Where goodwill has been allocated to a cash-generating unit (CGU) and part of the operation within that unit is disposed of, the goodwill associated with the disposed operation is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed in these circumstances is measured based on the relative values of the disposed operation and the portion of the cash-generating unit retained.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**c) Current and non-current classification**

The Group presents assets and liabilities in the statement of financial position based on current/non-current classification. An asset is current when it is:

- Expected to be realized or intended to sell or consumed in the normal operating cycle
- Held primarily for the purpose of trading
- Expected to be realized within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in the normal operating cycle
- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

The terms of the liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification. The Group classifies all other liabilities as non-current.

**d) Fair value measurement**

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits from the asset's highest and best use or by selling it to another market participant that would utilize the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorized within the fair value hierarchy. This is described, as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 - Quoted (unadjusted) market prices in active markets for identical assets or liabilities.

Level 2 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.

Level 3 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognized in the consolidated financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period. The Group determines the policies and procedures for both recurring fair value measurement, and for non-recurring measurement.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**d) Fair value measurement (continued)**

External valuers are involved for valuation of significant assets, whenever required. The involvement of external valuer is decided by the Group after discussion and approval by the Company's management. Selection criteria include market knowledge, reputation, independence and whether professional standards are maintained. The Group decides, after discussions with the Company's external valuer, which valuation techniques and inputs to use for each case.

At each reporting date, the Group analyses the movements in the values of assets and liabilities which are required to be remeasured or re-assessed as per the Group's accounting policies. For this analysis, the Group verifies the major inputs applied in the latest valuation by agreeing the information in the valuation computation to contracts and other relevant documents. The Group also compares the change in the fair value of each asset and liability with relevant external sources to determine whether the change is reasonable.

For the purpose of fair value disclosures, the Group has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above.

**e) Revenue recognition**

The Group generates its revenue from sale of pharmaceuticals and rendering of inpatient and outpatient services over time and at a point in time. Revenue is measured based on the consideration to which the Group expects to be entitled in a contract with a customer and excludes amounts collected on behalf of third parties. The goods and services are sold both on their own in separately identified contracts with customers and together as a bundled package of goods and/or services.

Revenue from contracts with customers is recognized when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods or services.

*Operating revenue*

Revenues are measured at the transaction price which is the amount of consideration that the Group expects to be entitled to in exchange for the services provided. Revenue primarily comprises fees charged for inpatient and outpatient hospital services. For operating revenues, the revenue is recognized when the treatment is provided, and the invoice is generated (i.e., after satisfaction of performance obligation). Net patient services revenue is recognized at the estimated net realizable amounts from the third-party payers (insurance and other companies) for the services rendered, net of estimated retroactive revenue adjustments when the related services are rendered. Unbilled revenue is recorded for the service rendered where the patients are not discharged, and final invoice is not raised for the services.

The normal business process associated with transactions with third-party payers involves review and inspection of submitted claims which occasionally results in an adjustment of invoiced amount. This adjustment could be for various technical or medical reasons resulting from review of submitted claims by third-party payers. These adjustments constitute a variable consideration and are assessed based on all information (historical, current and forecast) that is reasonably available to the Group and identify a reasonable number of possible consideration amounts. Some contracts include variable considerations such volume discount and prompt payment discount. Discounts comprise retrospective volume discounts granted to certain third-party payers on attainment of certain levels of business and constitute variable consideration. These are accrued over the course of the arrangement based on estimates of the level of business expected and are adjusted against revenue at the end of the arrangement to reflect actual volumes. Accordingly, the Group expects an amount of consideration that is less than what was originally invoiced. Management estimates variable consideration using the single most likely amount method for prompt payment discount.

Revenue from inpatient services is recognized over a period of time and outpatient services are recognized at the point in time.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**e) Revenue recognition (continued)**

*Sale of goods*

Sales of goods represents the invoiced value of medicines and drugs supplied by the Group. The Group's contracts with customers for the sale of medicines and drugs generally include one performance obligation. Revenue from sale of medicines and drugs is recognized at the point in time when control of the asset is transferred to the customer, generally on delivery/dispensing of the medicines and drugs.

*Interest income on term deposits*

Interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

*Rental income*

Rental income is recognized on a straight-line basis over the term of the lease. Lease incentives granted are recognized as an integral part of the total rental income, over the term of the lease.

*Dividend*

Dividend income from investments is recognized when the shareholders right to receive payment has been established.

**f) Foreign currency transactions**

*Transactions and balances*

Transactions in foreign currencies are translated to the respective functional currencies of Group entities at exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates, are generally recognized in profit or loss.

Foreign exchange gains and losses that relate to borrowings are presented in the statement of profit or loss, within finance costs. All other foreign exchange gains and losses are presented in the statement of profit or loss on a net basis within other income and expense.

Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are translated to the functional currency at the exchange rate at the date that the fair value was determined. Non-monetary items in a foreign currency that are measured in terms of historical cost are translated using the exchange rate at the date of the transaction. The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of the gain or loss on the change in fair value of the item (i.e., translation differences on items whose fair value gain or loss is recognized in OCI or profit or loss are also recognized in OCI or profit or loss, respectively).

*Group companies*

On consolidation, the assets and liabilities of foreign operations are translated into Saudi Riyals at the rate of exchange prevailing at the reporting date and their statements of profit or loss are translated at exchange rates prevailing at the dates of the transactions. The exchange differences arising on translation for consolidation are recognized in other comprehensive income (OCI). On disposal of a foreign operation, the component of OCI relating to that particular foreign operation is reclassified to profit or loss.

Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising on the acquisition are treated as assets and liabilities of the foreign operation and translated at the spot rate of exchange at the reporting date.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**g) Property and equipment**

Property and equipment excluding land and construction work in progress (CWIP) are carried at cost less accumulated depreciation and any accumulated impairment losses, if any.

Cost includes expenditure that is directly attributable to the acquisition of the asset. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably.

Expenditure incurred to replace a component of an item of property and equipment that is accounted for separately is capitalised and the carrying amount of the component that is replaced is written off. Other subsequent expenditure is capitalised only when it increases future economic benefits of the related item of property and equipment. All other expenditure is recognised in the consolidated statement of profit or loss as incurred.

Depreciation is calculated based on the estimated useful lives of the applicable assets on a straight-line basis commencing when the assets are ready for their intended use. The estimated useful lives, residual values and depreciation methods are reviewed at each statement of financial position date, with the effect of any changes in estimate accounted for on a prospective basis. Freehold land and properties under construction are not depreciated.

The following useful lives are used in the calculation of depreciation:

	<u>Years</u>
Buildings	33 years
Building system and improvements	3 to 10 years
Medical equipment and tools	4 to 10 years
Furniture and fixture	3 to 10 years
Motor Vehicles	4 years

An item of property and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. The gain or loss arising on the disposal or retirement of an item of property and equipment is determined as the difference between the net sales proceeds and the carrying amount of the asset and is recognised in the statement of profit or loss.

*Construction work in progress (CWIP)*

CWIP is recognized at cost less accumulated impairment, if any. CWIP is transferred to the related property and equipment when the construction or installation and related activities necessary to prepare the property and equipment for their intended use have been completed, and the property and equipment are ready for operational use.

Land is recognized at cost, less impairment, if any.

**h) Intangibles assets**

Intangible assets represent the software license and operating license of certain hospitals. They are accounted for using the cost model whereby capitalized costs are amortised on a straight-line basis over their estimated useful lives ranging between 3 to 10 years. Useful lives are reviewed at each reporting date.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**h) Intangibles assets (continued)**

*Intangible assets acquired separately*

Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortization and accumulated impairment losses, if any. Amortization is recognized on a straight-line basis over their estimated useful lives. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses.

*Derecognition of intangible assets*

An intangible asset is derecognized on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, and are recognized in profit or loss when the asset is derecognized.

*Impairment of tangible and intangible assets other than goodwill*

At the end of each reporting period, the Group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). When it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual cash-generating units, or otherwise they are allocated to the smallest group of cash-generating units for which a reasonable and consistent allocation basis can be identified.

Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment at least annually, and whenever there is an indication that the asset may be impaired.

Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognized immediately in profit or loss.

When an impairment loss subsequently reverses, the carrying amount of the asset (or a cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.

**i) Leases**

At inception of a contract, the Group assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**i) Leases (continued)**

**i) Group as a lessee**

At commencement or on modification of a contract that contains a lease component, the Group allocates the consideration in the contract to each lease component on the basis of its relative stand-alone prices. Currently, Group has no contract which includes lease and non-lease component.

The Group recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made on or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying assets to restore the underlying assets or the site on which it is located less any lease incentive returned.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term, unless the lease transfers ownership of the underlying asset to the Group by the end of the lease term or the cost of the right-of-use asset reflects that the Group will exercise a purchase option. In that case the right-of-use asset will be depreciated over the useful life of the underlying asset, which is determined on the same basis as those of property, plant and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Group's incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate.

The Group determines its incremental borrowing rate by obtaining interest rates from various external financing sources to reflect the terms of the lease and type of the asset leased.

Lease payments included in the measurement of the lease liability mainly comprise of fixed lease payments.

The lease liability is subsequently carried at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Group's estimate of the amount expected to be payable under a residual value guarantee, if the Group changes its assessment of whether it will exercise a purchase, extension or termination option or if there is a revised in-substance fixed lease payment.

When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

**Short-term leases and leases of low-value assets**

The Group has elected not to recognize right-of-use assets and lease liabilities for leases of low value assets and short-term leases including IT equipment. The Group recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term.



**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**i) Leases (continued)**

ii) Group as a lessor

The Group enters into lease agreements as a lessor with respect to some of its building properties.

Leases for which the Group is a lessor are classified as finance or operating leases. Whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases.

When the Group is an intermediate lessor, it accounts for the head lease and the sublease as two separate contracts. The sublease is classified as a finance or operating lease by reference to the right-of-use asset arising from the head lease.

Rental income from operating leases is recognized on a straight-line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognized on a straight-line basis over the lease term.

Amounts due from lessees under finance leases are recognized as receivables at the amount of the Group's net investment in the leases. Finance lease income is allocated to accounting periods so as to reflect a constant periodic rate of return on the Group's net investment outstanding in respect of the leases.

When a contract includes lease and non-lease components, the Group applies IFRS 15 to allocate consideration under the contract to each component.

**j) Borrowing costs**

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

**k) Financial instruments**

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

**i) Recognition and initial measurement**

Accounts receivable and debt securities issued are initially recognised when they are originated. All other financial assets and financial liabilities are initially recognised when the Group becomes a party to the contractual provisions of the instrument.

A financial asset (unless it is an accounts receivable without a significant financing component) or financial liability is initially measured at fair value plus, for an item not at fair value through profit or loss ("FVTPL"), transaction costs that are directly attributable to its acquisition or issue. Accounts receivable without a significant financing component is initially measured at the transaction price.

**ii) Financial assets**

On initial recognition, a financial asset is classified as measured at: amortized cost; fair value through OCI ("FVOCI"); or fair value through profit or loss ("FVTPL").

Financial assets are not reclassified subsequent to their initial recognition unless the Group changes its business model for managing financial assets, in which case all affected financial assets are reclassified on the first day of the first reporting period following the change in the business model.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**k) Financial instruments (continued)**

**ii) Financial assets (continued)**

A financial asset is measured at amortized cost if it meets both of the following conditions and is not designated as at FVTPL:

- it is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the Group may irrevocably elect to present subsequent changes in the investment's fair value in OCI. This election is made on an investment-by-investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. This includes all derivative financial assets. On initial recognition, the Group may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

**iii) Financial assets - Business model and assessment**

The Group makes an assessment of the objective of the business model in which a financial asset is held at a portfolio level because this best reflects the way the business is managed, and information is provided to management. The information considered includes:

- The stated policies and objectives for the portfolio and the operation of those policies in practice. These include whether management's strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities or expected cash outflows or realizing cash flows through the sale of the assets;
- How the performance of the portfolio is evaluated and reported to the Group's management;
- The risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;
- How managers of the business are compensated - e.g., whether compensation is based on the fair value of the assets managed or the contractual cash flows collected; and
- The frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity.

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Group's continuing recognition of the assets.

Financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.



**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**k) Financial instruments (continued)**

**vii) Derecognition**

**Financial assets**

The Group derecognises a financial asset when the contractual rights to the cash flows from the financial asset expires, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Group neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset. The Group enters into transactions whereby it transfers assets recognised in its statement of financial position, but retains either all or substantially all of the risks and rewards of the transferred assets. In these cases, the transferred assets are not derecognized.

**Financial liabilities**

The Group derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire. The Group also derecognises a financial liability when its terms are modified and the cash flows of the modified liability are substantially different, in which case a new financial liability based on the modified terms is recognised at fair value. On derecognition of a financial liability, the difference between the carrying amount extinguished and the consideration paid (including any non-cash assets transferred or liabilities assumed) is recognised in profit or loss.

**viii) Offsetting**

Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

**l) Impairment**

**i) Impairment of financial assets**

The Group recognises an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

The Group applies the general approach to provide for ECLs on all other financial instruments. ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

For accounts receivable and contract assets, the Group applies a simplified approach in calculating ECLs.

Therefore, the Group does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment. The Group assesses all the information available, including past due status, credit ratings, the existence of third party insurance and forward-looking economic factors in the measurement of the expected credit losses associated with its accounts receivable and contract assets.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**l) Impairment (continued)**

**i) Impairment of financial assets (continued)**

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the Group considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis, based on the Group's historical experience and informed credit assessment and includes forward-looking information.

If credit risk has not increased significantly since initial recognition or if the credit quality of the financial instruments improves such that there is no longer a significant increase in credit risk since initial recognition, loss allowance is measured at an amount equal to 12-month ECLs.

The Group assumes that the credit risk on a financial asset has increased significantly if it is more than 30 days past due.

The Group considers a financial asset to be in default when the borrower is unlikely to pay its credit obligations to the Group in full, without recourse by the Group to actions such as realising security (if any is held)

The Group considers a contract asset to be in default when the customer is unlikely to pay its contractual obligations to the Group in full, without recourse by the Group to actions such as realising security (if any is held).

The maximum period considered when estimating ECLs is the maximum contractual period over which the Group is exposed to credit risk.

***Measurement of ECLs***

ECLs are probability-weighted estimates of credit losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows due to the entity in accordance with the contract and the cash flows that the Group expects to receive). ECLs are discounted at the effective interest rate of the financial asset.

***Credit-impaired financial assets***

At each reporting date, the Group assesses whether financial assets carried at amortised cost are credit impaired. A financial asset is 'credit-impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

Evidence that a financial asset is credit-impaired includes the following observable data:

- significant financial difficulty of the debtor;
- a breach of contract such as a default;
- the restructuring of a loan or advance by the Group on terms that the Group would not consider otherwise;
- it is probable that the debtor will enter bankruptcy or other financial reorganisation; or the disappearance of an active market for a security because of financial difficulties.

***Presentation of allowance for ECLs in the statement of financial position***

Loss allowances for financial assets measured at amortised cost and contract assets are deducted from the gross carrying amount of these assets.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**l) Impairment (continued)**

**i) Impairment of financial assets (continued)**

***Write-off***

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Group determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write-off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Group's procedures for recovery of amounts due.

**ii) Impairment of non- financial assets**

The carrying amounts of the Group's non-financial assets, other than inventories and contract assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated. For goodwill the recoverable amount is estimated each year at the same time. An asset's recoverable amount is the higher of an asset's or CGU's fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.

The Group bases its impairment calculation on most recent budgets and forecast calculations, which are prepared separately for each of the Group's CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. A long-term growth rate is calculated and applied to projected future cash flows after the fifth year.

Impairment losses are recognised in profit or loss. Impairment losses recognised in respect of CGUs are allocated first to reduce the carrying amount of any goodwill allocated to the CGU (group of CGUs), and then to reduce the carrying amounts of the other assets in the CGU (group of CGUs) on a pro rata basis.

An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognised in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

An impairment loss in respect of an associate is measured by comparing the recoverable amount of the investment with its carrying amount in accordance with the requirements for non-financial assets. An impairment loss is recognised in profit or loss. An impairment loss is reversed if there has been a favourable change in the estimates used to determine the recoverable amount and only to the extent that the recoverable amount increases.

Goodwill that forms part of the carrying amount of an investment in an associate is not recognised separately, and therefore is not tested for impairment separately. Instead, the entire amount of the investment in an associate is tested for impairment as a single asset when there is objective evidence that the investment in an associate may be impaired.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**m) Inventories**

Inventories are stated at the lower of cost and net realizable value. Costs are those expenses incurred in bringing each product to its present location and condition and calculated on a weighted average basis. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale.

**n) Cash and cash equivalent**

For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash in hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts that are repayable on demand and that form an integral part of the Group's cash management are included in cash and cash equivalents. Bank overdrafts are shown within borrowings in current liabilities in the balance sheet, if any.

**o) Provisions**

Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the consolidated income statement net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a discount rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

*Decommissioning liability*

Decommissioning costs are provided for at the present value of expected costs to settle the obligation using estimated cash flows and are recognized as part of the cost of the relevant asset. The cash flows are discounted at a rate that reflects the risks specific to the decommissioning liability. The unwinding of the discount is expensed in the consolidated income statement as a finance cost. The estimated future costs of decommissioning are reviewed annually and adjusted as appropriate. Changes in the estimated future costs or in the discount rate applied, are added to or deducted from the cost of the asset.

**p) Contingencies**

Contingent liabilities are not recognized in the consolidated financial statements. These are disclosed unless the possibility of an outflow of resources embodying economic benefits is remote. Liabilities which are probable, are recorded in the consolidated statement of financial position under accounts payable and accruals. A contingent asset is not recognized in the consolidated financial statements but disclosed when an inflow of economic benefits is probable. A contingent asset becomes a realized asset recordable on the consolidated statement of financial position when the realization of cash flows associated with it becomes relatively certain.

**q) Zakat and tax**

*Zakat*

The Group is subject to the regulations of the Zakat, Tax and Custom Authority ("ZATCA") in the Kingdom of Saudi Arabia. Zakat is charged to the statement of profit or loss on an accruals basis. The zakat charge is computed on the Saudi shareholders' share of the zakat base at the end of the year. Any difference in the estimate is recorded when the final assessment is approved, at which time the provision is cleared.



**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**q) Zakat and tax (continued)**

**Zakat (continued)**

*Value added tax*

Expenses and assets are recognised net of the amount of value added tax ("VAT"), except:

- When the VAT incurred on a purchase of assets or services is not recoverable from the ZATCA, in which case, the VAT is recognised as part of the cost of acquisition of the asset or as part of the expense item, as applicable.
- When receivables and payables are stated with the amount of VAT included.
- The net amount of VAT recoverable from, or payable

**r) Employees' benefits**

*Retirement benefit costs and termination benefits*

For defined retirement benefit plans, the cost of providing benefits is determined using the projected unit credit method, with actuarial valuations being carried out at the end of each annual reporting period. Re-measurement, comprising actuarial gains and losses is reflected immediately in the statement of financial position with a charge or credit recognized in other comprehensive income in the period in which they occur. Re-measurement recognized in other comprehensive income is reflected immediately in retained earnings and will not be reclassified to profit or loss. Past service cost is recognized in profit or loss in the period of a plan amendment. Net interest is calculated by applying the discount rate at the beginning of the period to the net defined benefit liability or asset. Defined benefit costs are categorized as follows:

- service cost (including current service cost, past service cost, as well as gains and losses on curtailments and settlements);
- net interest expense or income; and
- re-measurement.

Curtailment gains and losses are accounted for as past service costs.

A liability for a termination benefit is recognized at the earlier of when the entity can no longer withdraw the offer of the termination benefit and when the entity recognizes any related restructuring costs.

*Short-term obligations*

Liabilities for wages and salaries, including non-monetary benefits, annual leave and accumulating sick leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in profit or loss in respect of employees' services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet. Liabilities recognized in respect of short-term employee benefits are measured at the undiscounted amount of the benefits expected to be paid in exchange for the related service.

**s) Segment reporting**

An operating segment is a component of the Group that engages in business activities from which it may earn revenue and incur expenses, including revenue and expenses that relate to transactions with any of the Group's other components. All operating segments' operating results are reviewed regularly by the Group's Chief Operating Decision Maker to make decisions about resources to be allocated to the segment and to assess its performance, and for which discrete financial information is available.

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**

**s) Segment reporting (continued)**

The Group's Board of Directors are considered to be the chief operating decision maker. Segment results that are reported to the Group's Chief Operating Decision Maker include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. As the operations of the Group are conducted in the Kingdom of Saudi Arabia, accordingly, for management purposes, the Group is organized into business units based on its products and services.

**t) Earnings per share**

Basic and diluted earnings per share is calculated by dividing the profit attributable to shareholders of the Company, excluding any costs of servicing equity other than ordinary shares by the weighted average number of ordinary shares outstanding during the financial year.

**u) Statutory reserves**

In accordance with Company's By-laws, the Company has established a statutory reserve by the appropriation of 10% of net income until the reserve equals 30% of the share capital. This reserve is not available for dividend distribution.

**v) Short term investments**

Short term investments in the statements position are deposits with having maturity of more than three months but less than a year from date of placement.

**w) Dividend distribution**

Dividend distribution to the Company's shareholders is recognised as a liability in the Group's financial statements in the period in which the dividends are approved by the Company's shareholders.

**x) Asset held for sale**

Non-current assets or disposal groups comprising assets and liabilities, are classified as held for sale if it is highly probable that they will be recovered primarily through sale rather than through continuing use.

Such assets, or disposal groups, are generally measured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on a disposal group is allocated first to goodwill, and then to the remaining assets and liabilities on a pro rata basis, except that no loss is allocated to inventories, financial assets, deferred tax assets, employee benefit assets, investment property or biological assets (if any), which continued to be measured in accordance with the Group's other accounting policies. Impairment losses on initial classification as held for sale or held for distribution and subsequent gains and losses on remeasurement are recognized in the consolidated statement of profit or loss.

Once classified as held for sale, intangible assets and property, plant and equipment are no longer amortized or depreciated, and any equity-accounted investee is no longer equity accounted.

Non-current assets classified as held for sale and the assets of a disposal group classified as held for sale are presented separately from the other assets in the statement of financial position.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**4. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS**

The preparation of the Group's consolidated financial statements in conformity with IFRS, as endorsed in KSA, requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. The Group based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Group. Such changes are reflected in the assumptions when they occur. Further, certain estimates and assumptions include the direct and indirect impact of the COVID-19 pandemic on the Group's business, financial condition and results of operations. The economic impact of the pandemic on the Group's business depends on its severity and duration, which in turn depend on highly uncertain factors. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

Judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

**a. Critical accounting estimates**

**i. Provision for expected credit losses of accounts receivable and contract assets**

The Group uses a provision matrix to calculate ECLs for accounts receivable and contract assets. The provision rates are based on days past due for groupings of various customer segments that have similar loss patterns (i.e. payor groups). The provision matrix is initially based on the Group's historical observed default rates. The Group will calibrate the matrix to adjust the historical credit loss experience with forward-looking information.

At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analyzed. The assessment of the correlation between historical observed default rates, forecast economic conditions and ECLs is a significant estimate. The amount of ECLs is sensitive to changes in circumstances and of forecast economic conditions. The Group's historical credit loss experience and forecast of economic conditions may also not be representative of customer's actual default in the future.

**ii. Employees' end-of-service benefits**

The cost of the employees' end-of-service benefits are determined using actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate and future salary increases. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

**iii. Revenue recognition – estimating variable consideration**

The Group estimates variable considerations to be included in the transaction price in respect of each of its agreement with customers. In making such estimate the Group assess the impact of any variable consideration in the contract, customers' right to volume discounts, prompt payment discounts and claims disallowance of certain services provided to the patients upon submission of invoices to the customers. The Group uses its accumulated historical experience to estimate the percentage. These percentages are applied to determine the expected value of the variable consideration. Any significant changes in experience as compared to historical return pattern will impact the expected adjustments estimated by the Group.

**iv. Impairment of non-financial assets**

Impairment exists when the carrying value of an asset or CGU exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on available data from binding sales transactions, conducted at arm's length for similar assets or observable market prices less incremental costs for disposing of the asset. The value in use calculation is based on a DCF model. The cash flows are derived from the budget and marketing terms forecast for the next five years and do not include restructuring activities that the Group is not yet committed to or significant future investments that will enhance the asset's performance of the CGU being tested. The recoverable amount is most sensitive to the discount rate used for the DCF model as well as the growth rate used for extrapolation purposes.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

---

**4. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS (continued)**

**a. Critical accounting estimates (continued)**

**v. Useful lives of property and equipment**

Management determines the estimated useful lives of property, plant and equipment for calculating depreciation. This estimate is determined after considering expected usage of the assets and physical wear and tear. Management reviews the residual value and useful lives annually and change in depreciation charges, if any, are adjusted in current and future periods.

**vi. Useful lives of intangible assets**

Management reviews the amortization period and the amortization method for any intangible asset with a finite useful life at least at each financial year-end. If the expected useful life of the asset is different from previous estimates, the Company changes the amortization period accordingly. If there has been a change in the expected pattern of consumption of the future economic benefits embodied in the asset, the Group changes the amortization method to reflect the changed pattern.

**vii. Zakat**

The Group is subject to Zakat in accordance with the Zakat, Tax and Custom Authority (“ZATCA”) regulations. Zakat computation involves relevant knowledge and judgement of the Zakat rules and regulations to assess the impact of Zakat liability at a particular period end. This liability is considered an estimate until the final assessment by ZATCA is carried out until which the Group retains exposure to additional Zakat liability.

**b. Critical judgements in applying accounting standards**

**i. Incremental borrowing rate for lease agreements**

The Group cannot readily determine the interest rate implicit in the lease agreement, therefore, it uses its Incremental Borrowing Rate (“IBR”) to measure lease liabilities. The IBR is the rate of interest that the Group would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. The IBR therefore reflects what the Group ‘would have to pay’, which requires estimation when no observable rates are available. The Group estimates the IBR using observable inputs, such as market interest rates when available and is required to make certain entity-specific estimates.

**ii. Determining the lease term of contracts**

The Group determines the lease term as non-cancellable term of the lease, together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

---

**5. NEW STANDARDS AND AMENDMENTS TO EXISTING STANDARDS**

*Amendments to existing standards adopted by the Group*

The Group has applied the following amendments for the first time for their annual reporting period commencing 1 January 2024:

- Non-current Liabilities with Covenants – Amendments to IAS 1 and Classification of Liabilities as Current or Non-current – Amendments to IAS 1, effective for annual periods beginning on or after 1 January 2024;
- Lease Liability in a Sale and Leaseback – Amendments to IFRS 16, effective for annual periods beginning on or after 1 January 2024;
- Supplier Finance Arrangements – Amendments to IAS 7 and IFRS 7, effective for annual periods beginning on or after 1 January 2024;
- IFRS S1 General Requirements for Disclosure of Sustainability-related Financial Information and IFRS S2 Climate-related Disclosures, effective for annual periods beginning on or after 1 January 2024;

However, these amendments did not have an impact on the consolidated financial statements of the Group. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

*Amendments to existing standards issued but not yet effective*

The amendments to existing standards that are issued, but not yet effective, up to the date of issuance of the Group's consolidated financial statements are disclosed below. The Group intends to adopt these amendments to existing standards, if applicable, when they become effective:

- Lack of Exchangeability – Amendments to IAS 21, effective for annual periods beginning on or after 1 January 2025;
- Amendments to the Classification and Measurement of Financial Instruments – Amendments to IFRS 9 'Financial Instruments' and IFRS 7 'Financial Instruments: Disclosures', effective for annual periods beginning on or after 1 January 2026;
- Annual improvements to IFRS Accounting Standards – Amendments to: IFRS 1 First-time Adoption of International Financial Reporting Standards, IFRS 7 Financial Instruments: Disclosures and its accompanying Guidance on implementing IFRS 7, IFRS 9 Financial Instruments, IFRS 10 Consolidated Financial Statements, and IAS 7 Statement of Cash flows, effective for annual periods beginning on or after 1 January 2026;
- IFRS 18 Presentation and Disclosure in Financial Statements, effective for annual periods beginning on or after 1 January 2027;
- IFRS 19 'Subsidiaries without Public Accountability: Disclosures', effective for annual periods beginning on or after 1 January 2027.
- Sale or Contribution of Assets between an Investor and its Associate or Joint Venture – Amendments to IFRS 10 and IAS 28, effective date deferred indefinitely.

The above-mentioned standards are not expected to have a significant impact on the consolidated financial statements of the Group.

**6. OPERATING SEGMENTS**

The Board of Directors monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on revenue & gross profit and is measured consistently in the consolidated financial statements.

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

**6. OPERATING SEGMENTS (CONTINUED)**

The Group's operations consist mainly of the medical services and sale of pharmaceuticals products and accordingly following are selected financial information as at 31 December 2024 and 2023 by business segment:

- Medical Services segment: Inpatient and outpatient services.
- Pharmaceuticals'.

No operating segments have been aggregated to form the above reportable operating segments.

	<b>Medical Services</b>	<b>Pharmaceuticals</b>	<b>Total</b>
<b>For the year ended 31 December 2024</b>			
<b>Revenue</b>	<b>2,428,198,536</b>	<b>451,173,805</b>	<b>2,879,372,341</b>
<b>Gross profit</b>	<b>1,147,143,304</b>	<b>141,821,231</b>	<b>1,288,964,535</b>
<b>For the year ended 31 December 2023</b>			
Revenue	2,312,553,391	392,954,730	2,705,508,121
Gross profit	1,202,566,762	110,512,476	1,313,079,238
<b>As at 31 December 2024</b>			
<b>Segment assets</b>	<b>5,132,659,756</b>	<b>270,139,987</b>	<b>5,402,799,743</b>
<b>Segment liabilities</b>	<b>1,528,752,905</b>	<b>160,476,825</b>	<b>1,689,229,730</b>
<b>As at 31 December 2023</b>			
Segment assets	4,716,319,267	248,227,330	4,964,546,597
Segment liabilities	1,391,618,392	146,081,489	1,537,699,881

**Geographical segments:**

All of the Group's operating assets and principal markets of activity are located in the Kingdom of Saudi Arabia.

The accounting policies of the reportable segments are the same as the Group's accounting policies. Segment profit represents the profit earned by each segment without allocation of the share of results of associates, central administration costs including directors' salaries, profit from term deposits, non-operating gains and losses in respect of financial instruments and finance costs. This is the measure reported to the Group's Board of Directors for the purpose of resource allocation and assessment of segment performance. Details regarding capital expenditure and investment in associate has been separately disclosed in these consolidated financial statements.

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

**7. PROPERTY AND EQUIPMENT**

	<b>Land</b>	<b>Buildings</b>	<b>Building system and improvement</b>	<b>Medical equipment and tools</b>	<b>Furniture and fixture</b>	<b>Motor vehicles</b>	<b>Construction work in progress</b>	<b>Total</b>
<b>Cost</b>								
1 January 2023	516,931,144	1,363,600,852	852,391,495	974,810,393	226,177,767	37,757,533	148,505,318	4,120,174,502
Additions	200,000	10,452,594	12,933,060	94,916,419	17,360,725	5,783,335	311,610,885	453,257,018
Transfers (note 7.3)	-	117,399,785	23,656,443	7,084,170	-	-	(148,140,398)	-
Write off	-	(478,281)	(36,563,830)	(117,781,545)	(26,374,173)	(473,693)	-	(181,671,522)
Disposals	-	-	(104,711)	(686,354)	(1,228,669)	(1,927,663)	-	(3,947,397)
31 December 2023	517,131,144	1,490,974,950	852,312,457	958,343,083	215,935,650	41,139,512	311,975,805	4,387,812,601
Additions	<b>208,638,670</b>	<b>12,354,022</b>	<b>7,649,781</b>	<b>60,851,713</b>	<b>20,568,430</b>	<b>8,669,168</b>	<b>373,895,690</b>	<b>692,627,474</b>
Transfers (note 7.3)	-	<b>62,144,815</b>	<b>52,640,955</b>	<b>80,123</b>	<b>14,620</b>	-	<b>(114,880,513)</b>	-
Write off	-	-	-	<b>(75,752)</b>	<b>(62,311)</b>	-	-	<b>(138,063)</b>
Disposals	<b>(160,000)</b>	-	<b>(5,713)</b>	<b>(2,596,270)</b>	<b>(433,434)</b>	<b>(4,734,508)</b>	-	<b>(7,929,925)</b>
<b>31 December 2024</b>	<b>725,609,814</b>	<b>1,565,473,787</b>	<b>912,597,480</b>	<b>1,016,602,897</b>	<b>236,022,955</b>	<b>45,074,172</b>	<b>570,990,982</b>	<b>5,072,372,087</b>
<b>Accumulated depreciation</b>								
1 January 2023	-	296,669,584	334,500,533	523,826,923	130,850,116	25,933,142	-	1,311,780,298
Depreciation charge for the year	-	38,628,072	76,141,686	75,918,241	19,473,643	4,796,084	-	214,957,726
Write off	-	(478,242)	(36,562,922)	(117,723,083)	(26,367,948)	(473,685)	-	(181,605,880)
Disposals	-	-	(104,695)	(395,590)	(1,213,954)	(1,734,751)	-	(3,448,990)
31 December 2023	-	<b>334,819,414</b>	<b>373,974,602</b>	<b>481,626,491</b>	<b>122,741,857</b>	<b>28,520,790</b>	-	<b>1,341,683,154</b>
Depreciation charge for the year	-	<b>41,718,491</b>	<b>79,124,204</b>	<b>82,546,983</b>	<b>20,174,282</b>	<b>4,881,660</b>	-	<b>228,445,620</b>
Write off	-	-	-	<b>(75,688)</b>	<b>(62,275)</b>	-	-	<b>(137,963)</b>
Disposals	-	-	<b>(4,198)</b>	<b>(2,415,030)</b>	<b>(383,906)</b>	<b>(4,467,286)</b>	-	<b>(7,270,420)</b>
<b>31 December 2024</b>	-	<b>376,537,905</b>	<b>453,094,608</b>	<b>561,682,756</b>	<b>142,469,958</b>	<b>28,935,164</b>	-	<b>1,562,720,391</b>
<b>Carrying amount</b>								
<b>As at 31 December 2024</b>	<b>725,609,814</b>	<b>1,188,935,882</b>	<b>459,502,872</b>	<b>454,920,141</b>	<b>93,552,997</b>	<b>16,139,008</b>	<b>570,990,982</b>	<b>3,509,651,696</b>
As at 31 December 2023	517,131,144	1,156,155,536	478,337,855	476,716,592	93,193,793	12,618,722	311,975,805	3,046,129,447

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

**7. PROPERTY AND EQUIPMENT (continued)**

7.1 Depreciation charge for the year has been allocated as follow:

	<u>Note</u>	<u>2024</u>	<u>2023</u>
Cost of operations	29	<b>182,666,883</b>	171,966,180
General and administration expenses	31	<b>45,778,737</b>	42,991,546
		<b><u>228,445,620</u></b>	<b><u>214,957,726</u></b>

7.2 As at 31 December 2024, plots of land amounting to SR 52.92 million (2023: SR 52.92 million) have been pledged as security against term loans from Ministry of Finance.

**7.3 Construction Work in progress:**

Construction work in progress mainly represents costs incurred to construct new hospitals and expansion of existing hospitals, which is currently in work-in-progress. During the year, Group has capitalised SR 114.88 million which majorly includes the staff accommodation building in Jubail amounting to SR 49.01 million.

7.4 In 2024, borrowing costs of SR 20.37 million (2023: SR 4.54 million) have been capitalized.

**8. GOODWILL**

On 24 July 2006, the Group acquired 51% of the voting shares of Eastern Medical Services Company Limited (“EMS”), an unlisted company registered in the Kingdom of Saudi Arabia. The Group performed its annual impairment test and compared the carrying value to their estimated recoverable amount based on appropriate method. The results of impairment test at 31 December 2024 indicated no impairment loss.

The recoverable amount of the EMS is also determined based on value in use calculation using cash flow projections from financial budgets approved by senior management covering a five-year period. The projected cash flows have been updated to reflect the increased demand for services. The pre-tax discount rate applied to the cash flow projections is 10.7% (2023: 11.29%). The long-term growth rate used to extrapolate the cash flows of the unit beyond the five-year period is 2% (2023: 2%). As a result of the analysis, the estimated recoverable amount exceeded its carrying amount by approximately SR 348.2 million (2023: SR 238 million) and management did not identify an impairment for this CGU.

**Key assumptions used in value in use calculations**

The calculation of value in use is most sensitive to the following assumptions:

- Gross margins
- Discount rates
- Growth rates used to extrapolate cash flows beyond the forecast period

Gross margins are based on average values achieved in the three years preceding the start of the budget period. These are increased over the budget period for anticipated efficiency improvements.

Discount rates represent the current market assessment of the risks specific to cash generating unit, regarding the time value of money and individual risks of the underlying assets which have not been incorporated in the cash flow estimates. The discount rate calculation is based on the specific circumstances of the Group and its operating segments and derived from its weighted average cost of capital (WACC). The WACC takes into account both debt and equity. The cost of equity is derived from the expected return on investment by the Group's investors. The cost of debt is based on the interest-bearing borrowings the Group is obliged to service. Segment-specific risk is incorporated by applying individual beta factors. The beta factors are evaluated annually based on publicly available market data.

Growth rate estimates are based on published industry research.

Management have considered and assessed reasonably possible changes for key assumptions and have not identified any instances that could cause the carrying amount of the CGU to exceed its recoverable amount. Management believes a reasonable range of increase or decrease in any of the assumptions within the projected cash flows would not change the outcome of the impairment analysis for the goodwill.



**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

**9. INTANGIBLE ASSETS**

	<b>Softwares</b>	<b>Operating licenses</b>	<b>Total</b>
<b>Cost</b>			
1 January 2023	28,810,079	11,020,899	39,830,978
Additions during the year	5,389,522	4,110,943	9,500,465
Written off during the year	(3,372,927)	(570,978)	(3,943,905)
31 December 2023	30,826,674	14,560,864	45,387,538
Additions during the year	<b>2,449,211</b>	<b>4,091,457</b>	<b>6,540,668</b>
Written off during the year	-	<b>(2,225,666)</b>	<b>(2,225,666)</b>
<b>31 December 2024</b>	<b>33,275,885</b>	<b>16,426,655</b>	<b>49,702,540</b>
<b>Accumulated amortization</b>			
1 January 2023	15,476,792	7,964,886	23,441,678
Amortization charge for the year	2,672,250	3,030,946	5,703,196
Written off during the year	(3,372,927)	(570,978)	(3,943,905)
31 December 2023	14,776,115	10,424,854	25,200,969
Amortization charge for the year	<b>2,999,963</b>	<b>3,542,959</b>	<b>6,542,922</b>
Written off during the year	-	<b>(2,225,666)</b>	<b>(2,225,666)</b>
<b>31 December 2024</b>	<b>17,776,078</b>	<b>11,742,147</b>	<b>29,518,225</b>
<b>Carrying amount</b>			
<b>31 December 2024</b>	<b>15,499,807</b>	<b>4,684,508</b>	<b>20,184,315</b>
31 December 2023	16,050,559	4,136,010	20,186,569

The amortization of intangible assets has been allocated as follows:

	<b>2024</b>	<b>2023</b>
Cost of operations (note 29)	<b>2,399,969</b>	2,137,801
General and administration expenses (note 31)	<b>4,142,953</b>	3,565,395
	<b>6,542,922</b>	5,703,196

**10. RIGHT-OF-USE ASSET**

The Group has contracted for lease of building in Madinah having a lease period of 11 years from the date of agreement with an option to renew thereafter on mutual consent. Lease payments agreed at the time of inception of lease, may change during the tenure of agreement based on mutual consent of both parties.

During 2023, lease rentals were reduced as Company returned certain portion of the leased asset to the lessor, accordingly the right of use assets and lease liabilities were modified as per the requirement of IFRS 16 Leases and resulted gain on modification has been recorded in this condensed consolidated statement of profit or loss and other comprehensive income.

During the year ended 31 December 2024, Company has recognised lease of land for the construction of hospital in Yanbu for 43 years for the agreement entered during 2022, with an option to renew thereafter on mutual consent. Company has recognised the impact on the opening balances during the year as the impact was immaterial. Lease payments are agreed at the time of inception and are fixed during the tenure of the agreement.

	<b>2024</b>	<b>2023</b>
1 January	<b>19,683,031</b>	27,596,156
Additions during the year	<b>3,412,725</b>	-
Effect of modification (note 24.2)	-	(5,101,263)
Depreciation expense	<b>(3,005,346)</b>	(2,811,862)
31 December	<b>20,090,410</b>	19,683,031

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

**10. RIGHT-OF-USE ASSET (CONTINUED)**

The depreciation of right-of-use asset has been allocated as follows:

	<u>2024</u>	<u>2023</u>
Cost of operations (note 29)	<u>2,404,277</u>	2,249,490
General and administration expenses (note 31)	<u>601,069</u>	562,372
	<u><b>3,005,346</b></u>	<u>2,811,862</u>

**11. INVESTMENT IN AN ASSOCIATE – HELD FOR SALE**

The Group has 50% share in Advance Medical Project Company ("AMPC"), a limited liability company registered in the Kingdom of Saudi Arabia. AMPC is engaged in operating ophthalmology, ears, noses and throats clinics. This investment is accounted for under the equity method and share in result of associate has been recorded in the consolidated statement of profit or loss and other comprehensive income for the year ended 31 December 2023.

During 2024, the Group has formally announced its decision to exit its investment in Advanced Medical Projects Co ("AMPC"). Earlier it was agreed to extend the memorandum of association ending on 31 December 2022 to the end of 2025. Subsequently, an amendment was made, and services were continued until the end of January 2024. Starting from 1 February 2024, Mouwasat hospital in Dammam provided services through their Mouwasat Eye Center. Pursuant to exit, Group does not have significant influence over AMPC.

Consequently, as of 31 December 2023, the Group classified investments in associates as held for sale in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations. This investment was carried at lower of fair value and carrying amount as management consider the fair value of investment approximate to the carrying value.

The movement in the investment during the year was as follows:

	<u>2024</u>	<u>2023</u>
1 January	-	18,788,375
Share in results	-	10,205,829
Dividends	-	(9,852,121)
Other comprehensive loss	-	(171,060)
Transferred to investment in associate held for sale	-	(18,971,023)
31 December	<u>-</u>	<u>-</u>

The financial information of the associate is not material at the Group level, therefore summarised financial information of the associate has not been presented.

During the year, the Group received a dividend of SR 10.21 million from AMPC, which was recognized as other income (note 31). In November 2024, a final settlement was agreed upon with AMPC, and the Group received SR 8.28 million as full and final settlement. As a result, a loss of SR 10.69 million was recognized on the sale of the investment in an associate held for sale.

**12. ADVANCES TO CONTRACTORS AND SUPPLIERS**

This represents advances made to contractor and supplier for hospital projects under progress and purchase of medical equipment. The movement in advances to contractors and suppliers was as follows:

	<u>2024</u>	<u>2023</u>
Balance as at 1 January	<u>244,460,781</u>	200,522,745
Payments during the year	<u>78,857,632</u>	215,617,973
Transfer to property and equipment	<u>(243,243,423)</u>	(171,679,937)
Balance as at 31 December	<u><b>80,074,990</b></u>	<u>244,460,781</u>

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

**13. INVENTORIES**

	<u>2024</u>	<u>2023</u>
Pharmaceuticals and cosmetic materials	<b>122,477,948</b>	100,165,384
Surgical and consumable tools	<b>100,105,098</b>	88,265,344
Other consumables	<b>9,481,951</b>	8,734,058
	<b><u>232,064,997</u></b>	<u>197,164,786</u>

No expense or reversal has been recognized in respect of impairment for inventories as expired inventories are recalled by the suppliers before the expiry date as per terms of agreement.

No write downs of inventory to net realisable value and of the reversal of such write-downs have been recognized because sales prices of pharmaceutical inventories are regulated by ministry of health and have not significantly changed subsequent to year end.

**14. ACCOUNTS RECEIVABLE**

	<u>2024</u>	<u>2023</u>
Accounts receivable	<b>1,017,462,327</b>	1,316,142,867
Less: Impairment loss (note 14.1)	<b>(92,414,684)</b>	(163,486,121)
	<b><u>925,047,643</u></b>	<u>1,152,656,746</u>

The Group's credit terms require receivables to be repaid within 30-60 days of the claim date depending on the type of customer, which is in line with healthcare industry. It is not the practice of the Group to obtain collateral over receivables and therefore are unsecured. No interest is charged on outstanding balance. As at 31 December 2024, approximately 94% of the Group's accounts receivable balance was due from various governmental and insurance entities (31 December 2023: 95%).

The Group always measures the loss allowance for accounts receivable at an amount equal to lifetime ECL. The expected credit losses are estimated using a provision matrix by reference to past default experience of the debtor and an analysis of the debtor's current financial position, adjusted for factors that are specific to the debtors, general economic conditions of the industry in which the debtors operate and an assessment of both the current as well as the forecast direction of conditions at the reporting date.

The Group writes off accounts receivable when there is information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery, i.e., when the debtor has been placed under liquidation or has entered into bankruptcy proceedings.

The following table details the risk profile of accounts receivable based on the Group's provision matrix. As the Group's historical credit loss experience does not show significantly different loss pattern for different customer segments.

	<u>Accounts receivable – days past due</u>					<u>Total</u>
	<u>Not past due</u>	<u>30-90</u>	<u>90-180</u>	<u>180-360</u>	<u>&gt;360</u>	
<b>31 December 2024</b>	<b>319,803,138</b>	<b>370,877,551</b>	<b>142,365,666</b>	<b>62,932,534</b>	<b>29,068,754</b>	<b>925,047,643</b>
31 December 2023	240,985,980	382,895,698	163,024,018	207,130,504	158,620,546	1,152,656,746

**14.1 Following is the movement of impairment loss on accounts receivable:**

	<u>2024</u>	<u>2023</u>
Balance at 1 January	<b>163,486,121</b>	72,501,282
Impairment loss on accounts receivables	<b>78,406,331</b>	117,256,160
Write offs	<b>(149,477,768)</b>	(26,271,321)
Balance at 31 December	<b><u>92,414,684</u></b>	<u>163,486,121</u>

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

**15. ADVANCES, PREPAYMENTS AND OTHER CURRENT ASSETS**

	<u>2024</u>	<u>2023</u>
Prepaid expenses	41,264,746	51,003,045
Advances to suppliers	26,998,281	22,974,918
Contract assets (note 28.1)	7,087,682	8,610,772
Other assets	12,389,227	16,368,542
	<u>87,739,936</u>	<u>98,957,277</u>

**16. TERM DEPOSITS**

As at 31 December 2024, Islamic term deposits of SR 85 million (2023: SR 100 million) were placed with a local bank with maturities of more than three months and earn commission income at fixed agreed rate specified in the placement letter. The agreed rate was prevailing market interest rate at the time of its placement.

**17. CASH AND CASH EQUIVALENTS**

	<u>2024</u>	<u>2023</u>
Cash in hand	446,219	409,514
Bank balances	116,128,537	48,639,992
Term deposits	310,000,000	-
	<u>426,574,756</u>	<u>49,049,506</u>

Cash and cash equivalents comprise cash at banks, cash in hand and term deposits with maturity less than three months which are subject to an insignificant risk of changes in value.

Balances with banks are assessed to have low credit risk of default since these banks are highly regulated by the central banks of the respective countries. None of the balances with banks at the end of the reporting period are past due, and taking into account the historical default experience and the current credit ratings of the bank, the management of the Company have assessed that there is no impairment, and hence have not recorded any loss allowances on these balances.

**18. SHARE CAPITAL**

The authorized, issued and fully paid share capital of the Company is divided into 200 million shares (2023: 200 million shares) of SR 10 each.

During the year 2022, the Company's board of directors recommended in its meeting held on 22 December 2022 for capital increase by granting free shares to the Company's shareholders, with one share for each of the shares owned on the day of the extra ordinary general meeting and registered in the Company's shareholder register. The share capital increase was proposed by way of capitalization of SR 1 billion from retained earnings. The proposed bonus shares issuance was approved by the Company's shareholders in an Extraordinary General Assembly Meeting held on 7 August 2023. During the year ended 31 December 2023, bonus shares were distributed, share capital was increased and accordingly all the legal formalities have been finalized.

**19. DIVIDENDS**

The Board of Directors at their meeting held on 22 Jumada Al-Akhirah1446H (corresponding to 23 December 2024) proposed a cash dividend of SR 2 per share amounting to SR 400 million for the year ended 31 December 2024G. The approval of the shareholders of the Group for the dividend shall be obtained in their forthcoming Annual General Meeting. The consolidated financial statements for the year ended 31 December 2024 do not include the effect of the aforementioned proposed dividend, which will be accounted for in the consolidated financial statements for the year ending 31 December 2025.

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

**19. DIVIDENDS (CONTINUED)**

The Board of Directors at their meeting held on 12 Jumada Al-Akhirah 1445H (corresponding to 25 December 2023G) proposed a cash dividend of SR 1.75 per share amounting to SR 350 million for the year ended 31 December 2023G. The approval of the shareholders of the Group for the dividend was obtained in their forthcoming Annual General Meeting. The dividend has been accounted for in the consolidated financial statements for the year ended 31 December 2024.

The Board of Directors at their meeting held on 28 Jumada Al-Awwal 1444H (corresponding to 22 December 2022G) proposed a cash dividend of SR 3 per share amounting to SR 300 million for the year ended 31 December 2022G, which was subsequently approved by shareholders in General Assembly Meeting held on 17 Shawwal 1444H (corresponding to 7 May 2023G), which has been accounted for in the consolidated financial statements for the year ended 31 December 2023.

**20. STATUTORY RESERVE**

In accordance with the By-laws of the Company, 10% of the profit for the year is required to be transferred to the statutory reserve until the balance in the reserve equals 30% of the capital.

**21. NON-CONTROLLING INTERESTS**

The following table summarises the information relating to the Group's subsidiaries (Eastern Medical Services Company "EMS", Jeddah Doctor Company "JDC" and Modawaa and Rieaya Medical Company Limited ("Modawaa") that has material non-controlling interests (NCI), before any intra group eliminations.

Summarized statements of financial positions

<b>31 December 2024</b>	<b>EMS</b>	<b>JDC</b>	<b>Modawaa</b>	<b>Total</b>
Non-current assets	<b>115,671,604</b>	<b>317,378,067</b>	-	<b>433,049,671</b>
Current assets	<b>141,417,792</b>	<b>2,289,722</b>	<b>1,000,000</b>	<b>144,707,514</b>
Non-current liabilities	<b>(20,109,175)</b>	<b>(140,425,942)</b>	-	<b>(160,535,117)</b>
Current liabilities	<b>(54,300,626)</b>	<b>(66,452,756)</b>	<b>(76,673)</b>	<b>(120,830,055)</b>
Net assets	<b>182,679,595</b>	<b>112,789,091</b>	<b>923,327</b>	<b>296,392,013</b>
<b>Attributable to:</b>				
Equity holder of parent	<b>93,166,603</b>	<b>57,522,434</b>	<b>470,897</b>	<b>151,159,934</b>
Non-controlling interests	<b>89,512,992</b>	<b>55,266,657</b>	<b>452,430</b>	<b>145,232,079</b>

<b>31 December 2023</b>	<b>EMS</b>	<b>JDC</b>	<b>Total</b>
Non-current assets	113,896,827	172,974,581	286,871,408
Current assets	132,451,789	5,051,743	137,503,532
Non-current liabilities	(20,099,128)	(10,553)	(20,109,681)
Current liabilities	(34,227,167)	(64,342,748)	(98,569,915)
Net assets	192,022,321	113,673,023	305,695,344
<b>Attributable to:</b>			
Equity holder of parent	97,931,393	57,973,239	155,904,632
Non-controlling interests	94,090,928	55,699,784	149,790,712

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

**21. NON-CONTROLLING INTERESTS (CONTINUED)**

Summarized statements of profit or loss and other comprehensive income for the year ended 31 December:

<b>31 December 2024</b>	<u>EMS</u>	<u>JDC</u>	<u>Modawaa</u>	<u>Total</u>
Revenue	264,224,246	-	-	264,224,246
Cost of sales	(141,798,231)	-	-	(141,798,231)
Selling and distribution expenses	(11,259,127)	(8,480)	-	(11,267,607)
General and administration expenses	(54,938,322)	(758,314)	(62,841)	(55,759,477)
Impairment loss on accounts receivables	(4,629,828)	-	-	(4,629,828)
Other income	13,679	-	-	13,679
Finance costs	(141,982)	-	-	(141,982)
Finance income	1,091,897	-	-	1,091,897
Profit / (loss) before zakat	52,562,332	(766,794)	(62,841)	51,732,697
Zakat for the year	(2,925,983)	(117,138)	(13,832)	(3,056,953)
Net profit / (loss) for the year	49,636,349	(883,932)	(76,673)	48,675,744
Other comprehensive gain for the year	1,020,925	-	-	1,020,925
Total comprehensive income for the year	<u>50,657,274</u>	<u>(883,932)</u>	<u>(76,673)</u>	<u>49,696,669</u>
Profit attributable to non-controlling interest	<u>24,321,811</u>	<u>(433,127)</u>	<u>(37,570)</u>	<u>23,851,114</u>
Total comprehensive income attributable to non-controlling interests	<u>24,822,064</u>	<u>(433,127)</u>	<u>(37,570)</u>	<u>24,351,367</u>
Dividends to non-controlling interest	<u>(29,400,000)</u>	<u>-</u>	<u>-</u>	<u>(29,400,000)</u>
<b>31 December 2023</b>	<u>EMS</u>	<u>JDC</u>	<u>Total</u>	
Revenue	255,509,638	-	255,509,638	
Cost of sales	(119,372,507)	-	(119,372,507)	
Selling and distribution expenses	(11,593,995)	-	(11,593,995)	
General and administration expenses	(53,748,819)	(1,298,749)	(55,047,568)	
Impairment loss on accounts receivables	(6,200,000)	-	(6,200,000)	
Other income	8,255	-	8,255	
Finance income	751,767	-	751,767	
Profit / (loss) before zakat	65,354,339	(1,298,749)	64,055,590	
Zakat for the year	(1,013,065)	(387,762)	(1,400,827)	
Net profit / (loss) for the year	64,341,274	(1,686,511)	62,654,763	
Other comprehensive loss for the year	(197,762)	-	(197,762)	
Total comprehensive income for the year	<u>64,143,512</u>	<u>(1,686,511)</u>	<u>62,457,001</u>	
Profit attributable to non-controlling interest	<u>31,527,224</u>	<u>(826,390)</u>	<u>30,700,834</u>	
Total comprehensive income attributable to non-controlling interests	<u>31,430,321</u>	<u>(826,390)</u>	<u>30,603,931</u>	
Dividends to non-controlling interest	<u>34,300,000</u>	<u>-</u>	<u>34,300,000</u>	

Summarised cash flow information for the year ended 31 December:

<b>31 December 2024</b>	<u>EMS</u>	<u>JDC</u>	<u>Modawaa</u>	<u>Total</u>
Cash from operating activities	91,875,682	19,259,761	-	111,135,443
Cash used in investing activities	7,237,579	(144,515,502)	-	(137,277,923)
Cash used in financing activities	(60,000,000)	125,000,000	1,000,000	66,000,000
Net increase / (decrease) in the cash and cash equivalents	<u>39,113,261</u>	<u>(255,741)</u>	<u>1,000,000</u>	<u>39,857,520</u>

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

**21. NON-CONTROLLING INTERESTS (CONTINUED)**

Summarised cash flow information for the year ended 31 December (continued):

31 December 2023	EMS	JDC	Total
Cash from operating activities	67,020,236	39,217,081	106,237,317
Cash used in investing activities	(262,458)	(39,251,600)	(39,514,058)
Cash used in financing activities	(70,000,000)	-	(70,000,000)
Net decrease in the cash and cash equivalents	(3,242,222)	(34,519)	(3,276,741)
Non-controlling interest percentage		<b>2024</b>	2023
Eastern Medical Services Company		<b>49%</b>	49%
Jeddah Doctor Company		<b>49%</b>	49%
Modawaa and Rieaya Medical Company Limited		<b>49%</b>	-

**22. LONG-TERM BORROWINGS**

	2024	2023
<b>Current</b>		
Loans from commercial banks (a)	<b>167,642,232</b>	259,443,829
Loans from Ministry of Finance (b)	<b>5,946,940</b>	6,590,230
	<b>173,589,172</b>	266,034,059
<b>Non-Current</b>		
Loans from commercial banks (a)	<b>501,150,062</b>	430,458,956
Loans from Ministry of Finance (b)	<b>63,643,792</b>	69,590,738
	<b>564,793,854</b>	500,049,694

Movement in bank loans and borrowings is as follows:

	2024	2023
Balance at 1 January	<b>766,083,753</b>	862,466,419
Additions	<b>245,000,000</b>	180,000,000
Payments made during the year	<b>(272,700,727)</b>	(276,382,666)
Balance at 31 December	<b>738,383,026</b>	766,083,753

- a) The Group obtained Islamic loans facilities from various local commercial banks. These loans are secured by promissory notes and corporate guarantees. The facilities are subject to commission at SIBOR plus an agreed margin.
- b) The Group obtained loans facility of SR 147.3 million from Ministry of Finance for expansions and building of new hospitals and purchase of medical equipment. The loans are secured by a mortgage on the Group's plots of land (refer note 7.2) and are repayable on equal annual installments. These loans do not carry any financial charges.
- c) As at 31 December 2024, the Group had SR 1,665 million of unutilized facilities available for drawdown from total facilities of SR 2,990 million (2023: SR 2,007 million of unutilized facilities available for drawdown from total facilities of SR 3,396 million).

The Group is required to comply with certain covenant under the loan facility agreements mentioned above. A future breach of covenants may lead to renegotiation. The covenants are monitored on a monthly basis by management, in case of potential breach, actions are taken by management to ensure compliance. The Group was in compliance with financial covenants as of 31 December 2024 and 31 December 2023.

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

**22. LONG-TERM BORROWINGS (CONTINUED)**

Following are the combined aggregate amounts of future maturities representing principal amounts of the term loans as at 31 December:

	<u>2024</u>	<u>2023</u>
Within one year	173,589,174	266,034,059
Later than one year but not later than five years	471,114,652	417,547,612
Later than five years	93,679,200	82,502,082
	<u>738,383,026</u>	<u>766,083,753</u>

**23. EMPLOYEES' BENEFITS**

The Group operates a defined benefit plan in line with the Labour Law requirement in the Kingdom of Saudi Arabia. The end-of-service benefit payments under the plan are based on the employees' final salaries and allowances and their cumulative years of service at the date of their termination of employment, as defined by the conditions stated in the Labour Laws of the Kingdom of Saudi Arabia. Employees' end-of-service benefit plans are unfunded plan.

*Amounts recognised in the consolidated statement of profit or loss and other comprehensive income*

The amounts recognised in the consolidated statement of profit or loss and other comprehensive income related to employee benefit obligations are as follows:

**Total amount recognized in profit or loss:**

	<u>2024</u>	<u>2023</u>
Current service cost	26,403,963	24,878,169
Interest cost on benefit obligation	7,180,120	6,536,605
	<u>33,584,083</u>	<u>31,414,774</u>

**Total amount recognised in other comprehensive income**

	<u>2024</u>	<u>2023</u>
Remeasurement loss arising from:		
Actuarial loss due to change in experience adjustments	13,557,439	1,867,710
Actuarial (gain) / loss due to change in financial assumptions	(9,580,579)	1,536,459
	<u>3,976,860</u>	<u>3,404,169</u>

**Movement in the present value of defined benefit obligation:**

	<u>2024</u>	<u>2023</u>
As at 1 January	153,800,438	137,079,848
Current service cost	26,403,963	24,878,169
Interest cost	7,180,120	6,536,605
Remeasurement losses on the obligation	3,976,860	3,404,169
Benefits paid during the year	(17,933,996)	(18,098,353)
As at 31 December	<u>173,427,385</u>	<u>153,800,438</u>

Significant assumptions used in determining the post-employment defined benefit obligation includes the following:

	<u>2024</u>	<u>2023</u>
Discount rate	5.25%	4.60%
Future salary increases	4.25%	4.85%
Mortality rates	WHO SA19	WHO SA19
Rates of employee turnover	Heavy	Heavy



**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

**23. EMPLOYEES' BENEFITS (CONTINUED)**

Assumptions regarding future mortality have been based on published statistics and mortality tables. For current year World Health Organization "WHO" 19 mortality table has been used (2023: World Health Organization "WHO" 19 mortality table was used) for Kingdom of Saudi Arabia. There is no major deviation in the mortality tables used.

A quantitative sensitivity analysis for discount rate assumption on the defined benefit obligation as at 31 December is shown below:

<u>Assumptions</u>	<u>Discount rate</u>	
	<u>0.5% increase</u>	<u>0.5% decrease</u>
<b>Sensitivity analysis</b>		
<b>Defined benefit obligation as at 2024</b>	<b>169,304,704</b>	<b>(177,702,572)</b>
Defined benefit obligation as at 2023	149,889,898	(158,024,344)
	<u>Future salary increase</u>	
	<u>0.5% increase</u>	<u>0.5% decrease</u>
<b>Defined benefit obligation as at 2024</b>	<b>177,723,653</b>	<b>(169,247,006)</b>
Defined benefit obligation as at 2023	157,993,805	(149,880,664)

The sensitivity analyses above have been determined based on a method that extrapolates the impact on the defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period. The sensitivity analysis is based on a change in a significant assumption, keeping all other assumptions constant. The sensitivity analysis may not be representative of an actual change in the defined benefit obligation as it is unlikely that changes in assumptions would occur in isolation of one another.

The following payments are expected against the defined benefit liability in future years:

	<u>2024</u>	<u>2023</u>
Year 1	<b>25,058,312</b>	21,792,960
Year 2	<b>52,254,895</b>	38,713,633
Year 3	<b>26,839,256</b>	25,363,086
Year 4	<b>28,067,329</b>	24,038,507
Year 5	<b>27,226,409</b>	25,573,426
Beyond 5 years	<b>136,901,671</b>	123,216,031
	<b>296,347,872</b>	258,697,643

**24. LEASE LIABILITIES**

The Group has contracted for lease of building having lease period of 11 years from the date of agreement with an option to renew thereafter on mutual consent. Lease payments agreed at the time of inception of lease, may change during the tenure of agreement based on mutual consent of both parties.

During 2023, lease rentals were reduced as Group returned certain portion of the leased asset to the lessor, accordingly the right of use assets and lease liabilities are modified as per the requirement of IFRS 16 Leases and resulted gain on modification has been recorded in this consolidated statement of profit or loss and other comprehensive income.

During 2024, Group has also contracted for a lease of land for the construction of hospital for 43 years from the date of agreement with an option to renew thereafter on mutual consent. Lease payments are agreed at the time of inception and are fixed during the tenure of the agreement.

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

**24. LEASE LIABILITIES (CONTINUED)**

Information about leases for which the Group is a lessee is presented below:

**24.1 Lease liabilities**

	<u>2024</u>	<u>2023</u>
1 January	22,395,185	29,694,954
Additions during the year	3,412,725	-
Effect of modification (note 24.2)	-	(5,494,788)
Interest expense	1,790,460	1,420,019
Payments	(4,302,463)	(3,225,000)
Balance as at 31 December	<u>23,295,907</u>	<u>22,395,185</u>
	<u>2024</u>	<u>2023</u>
Current portion	3,842,154	3,612,000
Non-current portion	19,453,753	18,783,185
<b>Balance as at 31 December</b>	<u>23,295,907</u>	<u>22,395,185</u>

**24.2 Amounts recognized in profit or loss**  
**Leases under IFRS 16**

	<u>2024</u>	<u>2023</u>
Interest on lease liabilities (note 33)	1,790,460	1,420,019
Depreciation on right-of-use assets (note 10)	3,005,346	2,811,862
	<u>2024</u>	<u>2023</u>
Effect of modification of lease liability (note 24.1)	-	5,494,788
Effect of modification of right-of-use asset (note 10)	-	(5,101,263)
Gain on modification of leases	-	393,525

**24.3 Leases as lessor**

The Group has rented out outlets within hospitals premises for a period of less than one year and has no material finance lease contract as a lessor.

**25. ACCOUNTS PAYABLE**

	<u>2024</u>	<u>2023</u>
Accounts payable	276,518,749	230,222,076
Retention payable (note 25.1)	331,759	1,484,658
	<u>276,850,508</u>	<u>231,706,734</u>

The average credit period on purchases of goods is three months. No interest is charged on the accounts payable outstanding balance. The Group has financial risk management policies in place to ensure that all payables are paid within the pre-agreed credit terms.

**25.1** Non-current retention payable amounting to SR 50,476,948 (2023: SR 34,434,661) represents retention amount payable to contractors, in accordance with contractual agreements for long term projects.

**26. ACCRUALS AND OTHER CURRENT LIABILITIES**

	<u>2024</u>	<u>2023</u>
Accrued employee cost	100,921,380	47,947,613
Accrued management incentives	41,965,842	39,145,119
Value added tax (VAT)	41,504,347	43,647,676
Accrued material and services cost	21,961,055	19,765,845
NPHIES accrual	18,404,919	25,352,553
Accrued finance cost	1,944,251	1,825,754
Other payables	1,753,662	6,619,482
	<u>228,455,456</u>	<u>184,304,042</u>

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

**27. ZAKAT**

The significant components of the zakat base of the Company under zakat regulations principally comprised of shareholders' equity, long-term borrowings and provisions at the end of the year, less deduction for the net book value of property, plant and equipment, investments and certain other items.

Some of the amounts have been adjusted in arriving at approximate zakat base and the zakat charge for the year.

Movement of zakat provision as follow:

	<u>2024</u>	<u>2023</u>
Balance at 1 January	<b>33,754,078</b>	25,977,290
Charge		
Current year	<b>34,117,865</b>	33,754,078
Prior year	<b>2,067,849</b>	4,944,989
	<b>36,185,714</b>	38,699,067
Payments during the year	<b>(35,821,927)</b>	(30,922,279)
Balance at 31 December	<b>34,117,865</b>	33,754,078

**Status of assessment:**

**Mouwasat Medical Services Company**

The Company has submitted its zakat returns up to year ended December 31, 2023, settled zakat as per the return and obtained the required certificates and official receipts. The assessments for the years up to 2016 were finalized and settled in 2018. Zakat, Tax and Custom Authority ("ZATCA") raised queries for years 2017 and 2018 and the Company has provided the relevant information. According to ZATCA portal, the inquiry case for these years were closed and ZATCA did not raise any Zakat differences. ZATCA raised assessments for years 2019 and 2020 with a total liability of SR 7.3 million. Company has submitted an objection against ZATCA's assessment for the year 2019 and 2020 and subsequent to the objection, ZATCA issued a revised assessment with a total liability of SR 5.2 million, on which the Company filed an appeal against the rejection with the Committee for Resolution of Tax Violations and Disputes "CRTVD" through the General Secretariat of Tax Committees "GSTC" portal. The CRTVD has issued its decision where it has rejected the Company appeal. Subsequently, the Company has appeal the CRTVD's decision with the Appellate Committee of Tax Violations and Dispute Resolution (ACTVDR). During 2024, the decision was issued in favor of the ZATCA. However, the Company submitted a reconsideration against the ACRTVD decision, and the reconsideration request is still under study by the ACTVDR. The Company received an assessment for the years 2021 and 2022 amounting to SR 2.4 million which has been finalized and paid. The assessment for the year 2023 is still under review by the ZATCA.

**Eastern Medical Services Company Limited**

The subsidiary has submitted its zakat returns up to year ended 31 December 2023, settled zakat as per the returns and obtained the required certificates and official receipts. The assessments for the years from 2013 to 2016 and for the year 2018 were finalized and settled in 2018. ZATCA raised an assessment for the year 2019 amounting to SR 0.663 million and the Company has submitted an objection against ZATCA's assessment for the year 2019. ZATCA issued a revised assessment rejecting the Company appeal. The Company filed an appeal against the rejection with the Committee for Resolution of Tax Violations and Disputes "CRTVD" through the General Secretariat of Tax Committees "GSTC" portal. During the period, the CRTVD issued its decision regarding the Company's appeal and partially accepted certain contentions of the Company. Subsequently, the Company has appeal the CRTVD's decision with the Appellate Committee of Tax Violations and Dispute Resolution (ACTVDR). Subsequent to the year end, the decision was issued in favor of ZATCA. The assessment for the years 2020 to 2023 are still under review by the ZATCA.

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

**27. ZAKAT (CONTINUED)**

**Status of assessment (continued):**

**Jeddah Doctor Company**

The subsidiary has submitted the zakat return up to year ended 31 December 2023, settled zakat as per the returns and obtained the required certificates and official receipts. The subsidiary has not received any assessments from Zakat, Tax and Customs Authority ("ZATCA") since inception.

**Modawaa and Rieaya Medical Company Limited**

The Company was established on 29 Dhu'al Qadah 1445H (corresponding to 6 June 2024) and has not yet submitted the zakat return since its establishment.

**28. REVENUE**

The Group generates revenue primarily from:

- Services relating to inpatient and outpatient; and
- Sale of pharmaceutical goods.

**Disaggregation of revenue**

In the following table, revenue from contracts with customers is disaggregated by service lines and timing of revenue recognition. All revenues are generated within Kingdom of Saudi Arabia.

<b>Revenue by service lines</b>	<b>2024</b>	<b>2023</b>
Medical services	<b>2,428,198,536</b>	2,312,553,391
Pharmaceuticals	<b>451,173,805</b>	392,954,730
	<b>2,879,372,341</b>	<b>2,705,508,121</b>

<b>Timing of revenue recognition</b>	<b>2024</b>	<b>2023</b>
Medical services and pharmaceuticals sales transferred at a point in time	<b>1,728,474,606</b>	1,639,043,858
Medical services transferred over time	<b>1,150,897,735</b>	1,066,464,263
	<b>2,879,372,341</b>	<b>2,705,508,121</b>

<b>As at 31 December</b>	<b>2024</b>	<b>2023</b>
Contract assets (note 28.1 and 15)	<b>7,087,682</b>	8,610,772
Refund liability (note 28.2)	<b>155,993,839</b>	106,084,803

**28.1 Contract assets:**

Contract assets are related to in-patients who were provided services during the reporting period but were not discharged or billed as of the reporting date.

**28.2 Refund liability:**

Certain contracts provide for discounts comprise retrospective volume discounts granted to third-party payers (insurance and other companies) on attainment of certain admission levels / certain levels of patient visits. The retrospective volume discounts give rise to variable consideration. Variable consideration is recognized as a revenue to the extent that it is highly probable that it will not reverse. Discounts are accrued over the course of the period based on the estimates of the level of business expected using single most likely amount method. This is adjusted at the end of the period to reflect actual volumes. Volume discounts are recorded as a reduction in revenue and liabilities are created based on these estimates.

	<b>2024</b>	<b>2023</b>
Balance at 1 January	<b>106,084,803</b>	105,108,775
Addition during the year	<b>155,710,516</b>	103,407,470
Adjusted during the year	<b>(105,801,480)</b>	(102,431,442)
Balance at 31 December	<b>155,993,839</b>	106,084,803

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

**29. COST OF OPERATIONS**

	<u>2024</u>	<u>2023</u>
Employees' cost	605,795,231	525,284,082
Material consumption	237,845,606	198,021,119
Depreciation (note 7)	182,666,883	171,966,180
Drug consumption	127,836,404	100,333,146
Repair and maintenance	52,390,773	42,903,114
Support services	32,928,896	28,891,224
Utilities	17,823,174	18,586,186
Depreciation on right-of-use of asset (note 10)	2,404,277	2,249,490
Amortization of intangible assets (note 9)	2,399,969	2,137,801
Others	18,964,019	19,614,287
	<u>1,281,055,232</u>	<u>1,109,986,629</u>

**30. SELLING AND MARKETING EXPENSES**

	<u>2024</u>	<u>2023</u>
Employee's cost	86,542,175	75,040,584
Advertisement and promotion	31,566,385	35,174,483
	<u>118,108,560</u>	<u>110,215,067</u>

**31. GENERAL AND ADMINISTRATION EXPENSES**

	<u>2024</u>	<u>2023</u>
Employees' cost	173,560,121	151,251,671
Depreciation (note 7)	45,778,737	42,991,546
Management bonus	27,726,293	13,825,149
Repair and maintenance	22,453,903	18,391,589
Executives' salaries	18,650,000	14,550,000
Support services	14,112,382	12,382,220
Board of directors' remuneration	10,695,000	4,150,003
NPHIES fee accrual (note 31.1)	8,906,915	25,230,061
Utilities	7,693,373	7,971,549
Office stationery and supplies	6,894,201	6,559,275
Amortization of intangible assets (note 9)	4,142,953	3,565,395
Legal and professional fees	2,679,251	2,913,070
Depreciation on right-of-use of asset (note 10)	601,069	562,372
Others	32,497,806	33,083,476
	<u>376,392,004</u>	<u>337,427,376</u>

**31.1** NPHIES fee accrual represents fee accrued during the year 2024 for using NPHIES portal which is a unified electronic service platform for health and insurance exchange services.

**32. OTHER INCOME**

	<u>2024</u>	<u>2023</u>
Dividend income from investment held for sale	10,205,829	-
Rental income	1,878,445	1,895,722
Gain on disposal of property and equipment	1,183,251	292,893
Others	5,632,685	6,487,098
	<u>18,900,210</u>	<u>8,675,713</u>

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

**33. FINANCE COST**

	<u>2024</u>	<u>2023</u>
Interest on Islamic loans	<b>28,664,844</b>	45,036,486
Interest on lease liabilities (note 24)	<b>1,790,460</b>	1,420,019
	<b><u>30,455,304</u></b>	<u>46,456,505</u>

**34. EARNINGS PER SHARE**

Basic and diluted earnings per share is calculated by dividing the net income for the period attributable to the shareholders of the Company by the weighted average number of outstanding shares during the period as follows:

	<u>2024</u>	<u>2023</u>
Profit for the period attributable to the shareholders of the Company	<b>645,759,043</b>	657,687,906
Weighted average number of outstanding shares during the year	<b>200,000,000</b>	200,000,000
Basic and diluted earnings per share attributable to the shareholders of the Company	<b><u>3.23</u></b>	<u>3.29</u>

The weighted average number of outstanding shares have been retrospectively adjusted for prior year to reflect the distribution of 100 million bonus shares during the year ended 31 December 2023.

**35. RELATED PARTY TRANSACTIONS AND BALANCES**

Related parties include the Company's shareholders, associated companies and their shareholders, key management personnel, Board of Directors, and entities controlled, jointly controlled or significantly influenced by such parties. Terms and conditions of these transactions are approved by the Group's management. During the year, the Group transacted with the following related parties:

<u>Related Party</u>	<u>Relationship</u>
Advance Medical Project Company ("AMPC")	Associate
Al-Mouwasat International Company	Owned by shareholder
AdVision Media Solution	Entity with significant influence

<u>Related Party</u>	<u>Nature of transaction</u>	<u>2024</u>	<u>2023</u>
Advance Medical Project Company ("AMPC")	- Revenue	<b>(460,008)</b>	(3,318,258)
	- Share in result	-	(10,205,829)
	- Purchase of services	<b>1,738</b>	5,564,459
	- Other services	<b>2,037,654</b>	4,437,356
	- Cost charged	<b>650,000</b>	-
Al-Mouwasat International Company	- Purchases	<b>38,162,449</b>	33,611,630
	- Rent expense	<b>2,667,500</b>	2,676,000
	- Other services	<b>(213,155)</b>	(87,889)
AdVision Media Solution	- Advertisement services	<b>22,003,164</b>	29,996,015

The breakdown of the amounts due to / due from related parties are as follows:

**a) *Due to related parties***

	<u>2024</u>	<u>2023</u>
Al-Mouwasat International Company	<b>4,373,873</b>	5,094,362
AdVision Media Solution	<b>3,854,923</b>	41,825
	<b><u>8,228,796</u></b>	<u>5,136,187</u>

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

---

**35. RELATED PARTY TRANSACTIONS AND BALANCES (CONTINUED)**

*b) Due from a related party*

	<u>2024</u>	<u>2023</u>
Advance Medical Project Company ("AMPC")	<u>-</u>	<u>916,431</u>

Amounts due to and due from related parties as at 31 December 2024 principally include balances related to the above mentioned transactions. Outstanding balances at the reporting date are unsecured, interest free and payable within 12 months in ordinary course of business. Prices and terms of payment of the above transactions are approved by the Group's management.

*c) Compensation to key management personnel*

The remuneration of directors and other members of key management personnel during the period was as follows:

	<u>2024</u>	<u>2023</u>
Salary and allowances	<u>30,600,000</u>	<u>19,640,000</u>
Incentives and other benefits	<u>15,822,397</u>	<u>18,879,348</u>
	<u>46,422,397</u>	<u>38,519,348</u>

The remuneration of directors and key executives is determined by the remuneration committee considering the performance of individuals and market trends. Board of Directors' fee of SR 10.35 million (2023: SR 3.85 million) have been included as part of key management personnel remuneration.

On 20 March 2023, the Board of Directors of Zakat, Tax, and Customs Authority (ZATCA) in the Kingdom of Saudi Arabia (KSA) approved the amendments to the Transfer Pricing Bylaws (TP Bylaws) to bring the following into effect: a) extend applicability of the Transfer Pricing (TP) provisions to Zakat paying entities; and b) introduced Advance Pricing Agreements (APA) provisions for Tax payers and Zakat payers and these amendments were subsequently approved by Ummul Qura on 14 April 2023. The amendments will be applicable for Financial Years (FYs) starting on or after 1 January 2024. Under these new requirements, Zakat paying entities will need to ensure that their transactions with related parties are priced at arm's length and will be required to submit a TP disclosure form and TP Affidavit with their Zakat returns along with other compliances as stipulated in the TP Bylaws. Currently management is assessing the impact of these amendments on transactions with related parties and will make necessary changes in policies, procedures and agreements with its related parties to comply with the requirement of TP By-laws.

**36. CONTINGENT LIABILITIES AND COMMITMENTS**

**Guarantees**

As of 31 December 2024, the Group's bankers have given guarantees, on behalf of the Group, amounting to SR 8.56 million (2023: SR 0.5 million) mainly in respect of performance guarantees to customers and others.

**Capital commitments**

As of 31 December 2024, the Group's capital commitments amounted to SR 342.68 million (2023: SR 484.24 million) relating to certain expansion projects.

As of 31 December 2024, the Group has outstanding letter of credits amounting to SR 8.69 million (2023: SR 7.88 million).

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

---

**37. FINANCIAL INSTRUMENTS**

**37.1 Financial instruments risk management objectives and policies**

The Group's principal financial liabilities comprise loans, lease liability, accounts payable, accrual and other payables. The main purpose of these financial liabilities is to finance the Group's operations. The Group's principal financial assets include accounts receivable, term deposits and cash and cash equivalents that derive directly from its operations.

The Group is exposed to market risk, credit risk and liquidity risk. The Group's senior management oversees the management of these risks. The Group's senior management regularly review the policies and procedures to ensure that all the financial risks are identified, measured and managed in accordance with the Group's policies and risk objectives. The Group does not engage into any hedging activities. The Board of Directors reviews and agrees policies for managing each of these risks, which are summarized below.

**Market risk**

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices comprise three types of risk: interest rate risk, currency risk and other price risk such as equity price risk and commodity price risk. Financial instruments affected by market risk include: loans and borrowings, deposits, and certain other financial instruments.

***Interest rate risk***

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group's exposure to the risk of changes in market interest rates relates primarily to the Group's long-term debt obligations with floating interest rates. Management monitors the changes in interest rates and believes that fair value and cash flow interest rate risks to the Group are not significant.

***Interest rate sensitivity***

The following table demonstrates the sensitivity to a reasonably possible change in interest rates on that portion of loans and borrowings. With all other variables held constant, the Group's profit before Zakat is affected through the impact on floating rate borrowings, as follows:

	<u>2024</u>	<u>2023</u>
Increase by 50 basis points	<u>(3,878,045)</u>	<u>(3,401,079)</u>
Decrease by 50 basis points	<u>3,878,045</u>	<u>3,401,079</u>

**Foreign Currency risk**

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Group's exposure to the risk of changes in foreign exchange rates relates primarily to the Group's operating activities (when revenue or expense is denominated in a different currency from the Group's functional currency).

The Group did not undertake significant transactions in currencies other than Saudi Riyals and US Dollars. Since Saudi Riyal is on a fixed parity with the US Dollar, the management believes that the Group does not have any significant exposure to currency risk.

**Commodity price risk**

The Group is exposed to the impact of market fluctuations of the prices of various inputs to cost of revenues including pharmaceuticals supplies. The Group prepares annual budgets and periodic forecasts including sensitivity analyses in respect of various levels of such materials to manage the risk.

**Credit risk**

Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Group is exposed to credit risk from its operating activities (primarily for accounts receivable) and from its investing activities, including deposits with banks and financial institutions.



**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

**37. FINANCIAL INSTRUMENTS (CONTINUED)**

**37.1 Financial instruments risk management objectives and policies (continued)**

**Credit risk (continued)**

	<u>2024</u>	<u>2023</u>
Cash in bank	426,128,537	48,639,992
Term deposits (note 16)	85,000,000	100,000,000
Accounts receivable (note 14)	925,047,643	1,152,656,746
Due from a related party (note 35)	-	916,431
Contract asset (28.1)	7,087,682	8,610,772
Other current assets	12,389,227	16,368,542
	<u>1,455,653,089</u>	<u>1,327,192,483</u>

*Accounts receivables*

Customer credit risk is managed by each business unit subject to the Group's established policy, procedures and control relating to customer credit risk management. Accounts receivable of the Group are spread across large number of customers comprising of Ministries, insurance companies, semi-government companies and individual patients. The Group holds the accounts receivable with the objective of collecting the contractual cash flows and therefore measures them subsequently at amortized cost using the effective interest method. The Group seeks to manage its credit risk with respect to customers by setting credit limits for individual customers, monitoring outstanding receivables and ensuring close follow ups. The management has established a credit policy under which each new insurance company is analyzed individually for creditworthiness before the Group's standard payment and delivery terms and conditions are offered. An impairment analysis is performed at each reporting date on an individual basis for major customers. In addition, a large number of minor receivables are grouped into homogenous groups and assessed for impairment collectively. The calculation is based on actual historical data. The Group evaluates the concentration of risk with respect to accounts receivable as low, as its customers are located in several jurisdictions and industries and operate in largely independent markets. Accounts receivable and contract assets are written off where there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan with the Group, management has fully exhausted recoveries through legal means and a failure to make contractual payments.

*Financial instruments and cash deposits*

Credit risk from balances with banks and financial institutions is managed by the Group's treasury department in accordance with the Group's policy. The Group seeks to manage its credit risk with respect to banks by only dealing with reputable banks having rating "Baa1" or better. The stated rating is as per the global bank ratings by Moody's Investors Service. At the reporting date, no significant concentration of credit risk were identified by the management.

*Due from a related party*

The Group is not significantly exposed to any credit risk on its receivables balance which are due from its related parties as all the balances are originated and settled between the Group companies on regular basis.

*Contract asset and other current assets*

Contract assets are not more than six months. The Group is not significantly exposed to any credit risk on these balances.

**Liquidity risk**

Liquidity risk is the risk that the Group will encounter difficulty in raising funds to meet commitments associated with financial instruments. Liquidity risk may result from an inability to realize financial assets quickly at an amount close to its fair value. The Group manages its liquidity risk by monitoring working capital and cash flow requirements on regular basis. The Group manages its liquidity risk by ensuring that bank facilities are available. The Group's term of sales and services provided require amounts to be paid within 30 to 60 days of the date of submitting the invoice. Accounts payable are normally settled within 60 to 90 days of the date of purchase.

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

**37. FINANCIAL INSTRUMENTS (CONTINUED)**

**37.1 Financial instruments risk management objectives and policies (continued)**

**Liquidity risk (continued)**

*Excessive risk concentration*

Concentrations arise when a number of counterparties are engaged in similar business activities, or activities in the same geographical region, or have economic features that would cause their ability to meet contractual obligations to be similarly affected by changes in economic, political or other conditions. Concentrations indicate the relative sensitivity of the Group's performance to developments affecting a particular industry.

In order to avoid excessive concentrations of risk, the Group's policies and procedures include specific guidelines to focus on the maintenance of a diversified portfolio. Identified concentrations of credit risks are controlled and managed accordingly. The table below summarizes the maturity profile of the Group's financial liabilities based on contractual undiscounted payments:

As at 31 December 2024	Carrying amount	Contractual undiscounted cash flows			
		Within 12 months	2 to 5 years	> 5 years	Total
Accounts payable	276,850,508	276,850,508	-	-	276,850,508
Due to related parties	8,228,796	8,228,796	-	-	8,228,796
Retention payable	50,476,948	-	50,476,948	-	50,476,948
Accruals and other payable	228,455,456	228,455,456	-	-	228,455,456
Refund liability	155,993,839	155,993,839	-	-	155,993,839
Loans and borrowings	738,383,026	211,217,721	530,413,737	95,015,182	836,646,640
Lease liabilities	23,295,907	3,842,154	16,845,368	12,084,404	32,771,926
	<b>1,481,684,480</b>	<b>884,588,474</b>	<b>597,736,053</b>	<b>107,099,586</b>	<b>1,589,424,113</b>

As at 31 December 2023	Carrying amount	Contractual undiscounted cash flows			
		Within 12 months	2 to 5 years	> 5 years	Total
Accounts payable	231,706,734	231,706,734	-	-	231,706,734
Due to related parties	5,136,187	5,136,187	-	-	5,136,187
Retention payable	34,434,661	-	34,434,661	-	34,434,661
Accruals and other payable	184,304,042	184,304,042	-	-	184,304,042
Refund liability	106,084,803	106,084,803	-	-	106,084,803
Loans and borrowings	766,083,753	303,411,804	468,531,088	84,037,121	855,980,013
Lease liabilities	22,395,185	3,612,000	15,507,750	8,058,000	27,177,750
	<b>1,350,145,365</b>	<b>834,255,570</b>	<b>518,473,499</b>	<b>92,095,121</b>	<b>1,444,824,190</b>

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

**37. FINANCIAL INSTRUMENTS (CONTINUED)**

**37.1 Financial instruments risk management objectives and policies (continued)**

*Reconciliation of movements of liabilities to cash flows arising from financing activities*

	Note	Liabilities		Equity				Total
		Long term loan (including related accrued finance cost)	Lease liabilities	Share capital	Statutory reserve	Retained earnings	Non-controlling interest	
<b>Balance at 1 January 2024</b>		<b>767,909,507</b>	<b>22,395,185</b>	<b>2,000,000,000</b>	<b>365,768,791</b>	<b>911,287,213</b>	<b>149,790,712</b>	<b>4,217,151,408</b>
<b>Changes from financing cash flows</b>								
Proceeds from long-term loans	22	245,000,000	-	-	-	-	-	245,000,000
Repayment of long-term loans	22	(272,700,727)	-	-	-	-	-	(272,700,727)
Payment of lease liabilities		-	(2,512,003)	-	-	-	-	(2,512,003)
Interest paid		(48,912,598)	(1,790,460)	-	-	-	-	(50,703,058)
<b>Total changes from financing cash flows</b>		<b>(76,613,325)</b>	<b>(4,302,463)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(80,915,788)</b>
<b>Other change</b>								
Interest expense	33	28,664,844	1,790,460	-	-	-	-	30,455,304
Interest capitalised		20,366,251	-	-	-	-	-	20,366,251
Addition in lease liabilities	24	-	3,412,725	-	-	-	-	3,412,725
<b>Total liability related changes</b>		<b>49,031,095</b>	<b>5,203,185</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>54,234,280</b>
<b>Total equity related changes</b>		<b>-</b>	<b>-</b>	<b>-</b>	<b>64,575,904</b>	<b>226,706,026</b>	<b>(4,558,633)</b>	<b>286,723,297</b>
<b>Balance at 31 December 2024</b>		<b>740,327,277</b>	<b>23,295,907</b>	<b>2,000,000,000</b>	<b>430,344,695</b>	<b>1,137,993,239</b>	<b>145,232,079</b>	<b>4,477,193,197</b>

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

**37. FINANCIAL INSTRUMENTS (CONTINUED)**

**37.1 Financial instruments risk management objectives and policies (continued)**

*Reconciliation of movements of liabilities to cash flows arising from financing activities (continued)*

	Note	Liabilities		Equity				Total
		Long term loan (including related accrued finance cost)	Lease liabilities	Share capital	Statutory reserve	Retained earnings	Non-controlling interest	
Balance at 1 January 2023		865,610,810	29,694,954	1,000,000,000	300,000,000	1,622,846,424	153,486,781	3,971,638,969
Changes from financing cash flows								
Proceeds from long-term loans	22	180,000,000	-	-	-	-	-	180,000,000
Repayment of long-term loans	22	(276,382,666)	-	-	-	-	-	(276,382,666)
Payment of lease liabilities		-	(1,804,981)	-	-	-	-	(1,804,981)
Interest paid		(50,894,189)	(1,420,019)	-	-	-	-	(52,314,208)
Total changes from financing cash flows		(147,276,855)	(3,225,000)	-	-	-	-	(150,501,855)
Other change								
Interest expense	33	45,036,486	1,420,019	-	-	-	-	46,456,505
Interest capitalised		4,539,066	-	-	-	-	-	4,539,066
Effect of modification		-	(5,494,788)	-	-	-	-	(5,494,788)
Total liability related changes		49,575,552	(4,074,769)	-	-	-	-	45,500,783
Total equity related changes		-	-	1,000,000,000	65,768,791	(711,559,211)	(3,696,069)	350,513,511
Balance at 31 December 2023		767,909,507	22,395,185	2,000,000,000	365,768,791	911,287,213	149,790,712	4,217,151,408

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

(All amounts in Saudi Riyals unless otherwise stated)

**37. FINANCIAL INSTRUMENTS (CONTINUED)**

**37.1 Financial instruments risk management objectives and policies (continued)**

**Capital management**

The primary objective of the Group's capital management is to ensure that it maintains a strong credit rating and healthy capital ratios in order to support its business and maximize shareholder value. The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares.

In order to achieve this overall objective, the Group's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants may lead to negotiation. There have been no breaches of the financial covenants of any loans and borrowing in the current period. No changes were made in the objectives, policies or processes for managing capital during the year ended 31 December 2024 and 31 December 2023.

**Accounting classifications and fair values**

The following table shows the carrying value of financial assets and financial liabilities. As at 31 December 2024 and 2023, all financial assets and financial liabilities of the Group are categorized as held at amortized cost. Management believes that the fair values of the Group's financial assets and liabilities are not materially different from their carrying values.

**37.2 Financial assets**

	<u>2024</u>	<u>2023</u>
Accounts receivable (note 14)	925,047,643	1,152,656,746
Due from related parties (note 35)	-	916,431
Contract asset (note 15)	7,087,682	8,610,772
Term deposits (note 16)	85,000,000	100,000,000
Cash and cash equivalents (note 17)	426,574,756	49,049,506
Other current assets	12,389,227	16,368,542
Total financial assets not measured at fair value	<u>1,456,099,308</u>	<u>1,327,601,997</u>

**37.3 Financial liabilities**

	<u>2024</u>	<u>2023</u>
Loans and borrowings (note 22)	738,383,026	766,083,753
Lease liabilities (note 24)	23,295,907	22,395,185
Accounts payable (note 25)	276,850,508	231,706,734
Due to related parties (note 35)	8,228,796	5,136,187
Retention payable (note 25.1)	50,476,948	34,434,661
Refund liability (note 28.2)	155,993,839	106,084,803
Other current liabilities	144,831,473	88,918,486
Total financial liabilities not measured at fair value	<u>1,398,060,497</u>	<u>1,254,759,809</u>

**37.4 Measurement of fair values**

The Group's principal financial assets include cash and cash equivalents, accounts receivable and certain other receivables that arise directly from its operations. The Group's principal financial liabilities comprise long-term borrowings and accounts payable, due to related parties and other payables. The main purpose of these financial liabilities is to finance the Group's operations. Due to the short-term nature of the financial assets and financial liabilities classified as current assets and current liabilities, their carrying amounts are approximate to be the same as their fair values. For non-current financial liabilities, management consider that the fair values not significantly different from their carrying amounts.

**MOUWASAT MEDICAL SERVICES COMPANY**  
(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**  
(All amounts in Saudi Riyals unless otherwise stated)

---

**38. SUBSEQUENT EVENTS**

There are no significant subsequent events occurred since 31 December 2024 that would have a material impact on the financial position or financial performance of the Group.

**39. COMPARATIVE FIGURES**

Certain comparative figures have been reclassified to comply with the current period presentation of the consolidated financial statements.

**40. APPROVAL OF THE CONSOLIDATED FINANCIAL STATEMENTS**

These consolidated financial statements have been approved by the Board of Directors on 10 Ramadan 1446H, corresponding to 10 March 2025G.